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9PREFACE
O homem é do tamanho do seu sonho.
(A Man is the size of his dream)
Fernando Pessoa
 A scientific breakthrough requires hard-work, a significant amount of hours dedi-
cated to a specific problem and reproducible methods to validate the discovery. 
However, one needs a fair amount of creativity to address new questions and the 
ability to dream about unthinkable scenarios that might lead to unexpected find-
ings. When I started my first year of medical school, I was far from imaging that I 
would pursue a Ph.D. and perform all my research at Johns Hopkins University. Af-
ter completing the second year of my medical degree at Faculdade de Medicina da 
Universidade do Porto, Prof. Adelino Leite Moreira involved me in research projects 
studying pulmonary hypertension in animal models. At that time, Prof. Tiago Hen-
riques-Coelho was very interested in understanding the roles of a peptide, thymu-
lin, in the pathophysiology of pulmonary hypertension. With kindness and patience, 
Profs. Leite Moreira and Henriques-Coelho introduced me to the fundamental steps 
of scientific method and the laboratory routine, and at the same time encouraged 
me to come to the United States as a summer student to enrich my knowledge and 
mature scientific ideas. Therefore, I spent two summers doing research while in 
medical school, one at Maine Medical Center with Prof. Calvin Vary working in en-
doglin and TGFb signaling, and another at Harvard Medical School supervised by 
Prof. Tiago Outeiro developing an assay for studying protein oligomerization in Par-
kinson’s disease. Tiago and I were already good friends at the time, and few years 
later when he returned to Portugal to start his own laboratory, Tiago assigned me a 
project focused on renal tubular dysenesis, a kidney disease caused by misfolding 
of an important enzyme. I had just graduated from medical school and was about 
to start my internship, so I started experiencing the physician-scientist life: clinical 
commitments in the morning and early afternoon; basic research at late hours and 
throughout the weekend. I am very grateful to Tiago and the members of his labora-
tory, namely Rita Oliveira, Leonor Fleming, and Sandra Tenreiro, who taught me the 
fundamental techniques of cellular and molecular biology.
 In the middle of crowded emergency rooms and unexpected scientific results, 
Pipa, an oncology resident at the time, got my attention and my mind was no 
longer only divided between science and medicine, but also between Portugal 
and the United States. A few months after we met, Pipa was offered a position for 
a residency program in Washington, DC and I was about to start urology residency 
at Hospital de Santo António, Porto. As any first year urology resident, one of the 
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clinical tasks assigned to me was to perform prostate biopsies. I became intrigued 
with the fact that besides all the advances in medical imaging and cancer diagnos-
tics, urologists still struggle to detect prostate cancers and there is an unmet need 
for new predictors of outcome. In Europe and in the USA there are prostate cancer 
screening programs using prostate-specific antigen (PSA) serum levels. In general, 
men with elevated PSA levels are recommended to undergo a prostate biopsy to 
detect cancer at an early stage. However, this improvement in diagnosis resulted 
in overtreatment of harmless low-grade tumors. Only men with aggressive cancers 
are likely to derive any survival benefit from treatment and prostate biopsies often 
do not accurately distinguish indolent from aggressive cancers. Therefore, I decided 
to interrupt my residency training and move to the United States (meanwhile Pipa 
and I were engaged and planning to get married) and devote my Ph.D. research to 
the understanding of molecular mechanisms involved in prostate cancer progres-
sion and metastasis. All the bench work of this Ph.D. project was performed at the 
Departments of Pathology and Oncology of Johns Hopkins School of Medicine, Bal-
timore supervised by Prof. David Berman. I am profoundly grateful to Prof. Berman 
for accepting me in his laboratory as his mentee, for all his challenging scientific 
questions that became cornerstones to begin a solid scientific career. I also wish 
to thank my colleagues at the Berman laboratory and other collaborative labora-
tories, particularly William Brandt, Brian Simons, Luigi Marchionni, Tamara Lotan, 
Edward Schaeffer, Ashley Ross, Zhenhua Huang, Zeshaan Rasheed, Emmanuel 
Antonarakis and William Matsui, for their help, advice and scientific input to all the 
projects. My gratitude also to my co-mentors Prof. Rui Henrique and Prof. Carlos 
Lopes, who always made short the distance between USA and Portugal. I should 
also acknowledge financial support from Fundação para a Ciência e Tecnologia 
through a Ph.D. scholarship. 
 A special final word of gratefulness to Pipa for all her love, patience and incen-
tive throughout these years; and to my parents, sister and the rest of the family that 
although far away continuously supported me. 
 The structure of this Thesis is well accepted by Instituto de Ciências Biomêdicas 
Abel Salazar, Universidade do Porto and other academic institutions. The Thesis is 
written in English because all the results have already been published or submit-
ted for publication in peer-reviewed international scientific journals contributing to a 
broad spectrum of potential readers. I should mention that the contents of the The-
sis surpass the initial project that motivated the official title — Notch signaling path-
way as a mediator for early detection and modulation of aggressiveness of prostate 
cancer — proposed in the beginning of experimental work. The main focus of this 
Thesis is the molecular mechanisms involved in prostate cancer progression and 
metastasis. The Thesis is organized in five sections: an Introduction paper providing 
an overview of Notch pathway in cancer, particularly in prostate cancer, highlighting 
questions that remain open in the field; the “Rationale and Aims” present the main 
goals of my research projects; a summary of all the “Materials and Methods” used 
in all the experiments to generate the results; a section of “Results and Discussion” 
contains 3 original papers focused on different aspects of prostate cancer progres-
sion; and to conclude a list of references and a summary of the Thesis in English 
and Portuguese. Overall, the results presented in this Thesis provide new insights 
into the roles of Notch pathway members in prostate cancer progression, the ben-
efit of molecular markers in distinguishing indolent from aggressive tumors, and the 
biological activity of prostate circulating tumor cells. 
Washington, D.C., October 15, 2013
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NOTCH SIGNALING IN PROSTATE CANCER: A MOVING TARGET
Filipe LF Carvalho1, Brian W. Simons1,2, Charles G. Eberhart1, David M Berman1,3,4
1Department of Pathology, 2Department of Molecular and Comparative Pathobiology, 
3Urology and Oncology, Johns Hopkins University School of Medicine, Baltimore, 
Maryland, USA, 4Department of Pathology and Molecular Medicine and Cancer 
Biology and Genetics Program, Cancer Research Institute, Queen’s University, 
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Abstract
 By regulating cell fate, Notch pathway signaling provides critical input into differ-
entiation, organization and function of multiple tissues. Notch signaling is becoming 
an increasingly recognized feature of a number of cancers, where it may play onco-
genic or tumor suppressive roles. In benign prostate, Notch controls the proportion 
of cells with stem cell properties, as well as the differentiation state and architecture 
of the gland. In prostate cancer, similar features correlate with lethal potential and 
may be influenced by Notch. Increased Notch1 can confer a survival advantage 
on prostate cancer cells, and levels of Notch family members, such as Jagged2, 
Notch3 and Hes6 increase with higher cancer grade. However, Notch signaling can 
also antagonize growth and survival of both benign and malignant prostate cells. 
Since Notch antagonists are being tested in clinical trials for cancer, it will be criti-
cally important to know whether Notch normally supports or suppresses prostate 
cancer progression prior to applying this body of research to patient care. Here we 
review the operation of Notch signaling in prostate development and disease and 
point out further opportunities for therapeutic, diagnostic, and biologic inquiry. 
Keywords: Notch pathway; tumor progression; prostate cancer; active surveillance, 
targeted therapy 
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How Notch regulates cell fate and tissue organization
General roles for Notch in biology
 Named for the notched wing phenotype of mutant Drosophila and encoding a fam-
ily of evolutionarily conserved cell surface receptors, Notch is one of the most widely 
studied pathways in biology (1). Notch signaling has especially dramatic effects on 
cell fate, determining the shape and composition of organs and tissues throughout 
the animal(2). For example, Notch signaling in intestinal stem cells favors entero-
cyte rather than endocrine differentiation (3), whereas in lymphopoietic precursors, 
Notch activation favors the development of T cell over B cell progeny (4). These cell 
fate decisions typically occur in a specialized stem cell niche where stem cells and 
progeny monitor each other’s differentiation states. Notch signaling requires direct 
contact between the sending and receiving cells (see below), and is therefore well 
suited for this purpose. 
General mechanisms of Notch signaling
 To initiate Notch signaling, a membrane-bound ligand on the sending cell binds to 
a receptor on the receiving cell (Fig. 1A). Ligand binding catalyzes a unique series 
of proteolytic cleavages that convert the full-length membrane-bound receptor into 
a smaller transcriptional transactivator, the notch intracellular domain (NICD), which 
is released from the cell surface and translates into the nucleus (Fig. 1B). NICDs 
bind to RBPJ/CBP transcription factors to activate Notch target genes, including 
those encoding members of the Hairy and enhancer of split (HES) and the Hairy/
enhancer-of-split related with YRPW motif (HEY) protein families (Fig. 1B). Notably, 
these well-established pathway components have less well known family members 
with emerging roles in the prostate. Two examples of particular interest in the pros-
tate are DLK1 and HES6. DLK1 (Delta like 1 homolog) is highly related to delta li-
gands, but lacks the Delta-Serrate-LAG–2 (DSL) activating domain and is therefore 
likely a naturally occurring antagonist of Notch signaling (5). HES6 is structurally 
related with other HES family members, such as HES1, but is not a direct target of 
cannonical Notch signaling. In fact, HES6 determines an opposite cell fate in neural 
stem cells than HES1, a well established Notch target (6). 
 Research into Notch function in the prostate and other organs has been skewed 
towards Jagged1, Delta-like 1 and Notch1. A more complete understanding of Notch 
function will require additional attention to other Notch receptors and ligands.
Figure 1 — A In mammals, the pathway is composed of four receptors (Notch1 through Notch4) and five 
ligands (Jagged1 and 2 and Delta-like 1, 3, and 4). Both ligands and receptors are single-pass transmembrane 
proteins composed by different structural domains. Ligands have an extracellular domain with three related 
structural motifs: the Delta/Serrate/LAG–2 (DSL) motif; the Delta and OSM–11-like proteins (DOS) motif; and 
the third motif is compose of EGF-like repeats, both calcium binding and non calcium-binding, that can af-
fect signaling efficiency. Jagged ligands also have a citosine-rich (C-rich) domain. The extracellular domain of 
Delta-like 1 homolog (DLK1) only has a DOS motif and EGF repeats. The structure of the transmembrane and 
intracellular portion of the ligands remains largely unknown. Notch receptors have an extracellular domain that 
contains EGF-like repeats and a negative regulatory region; a transmembrane domain; and an intracellular do-
main composed RBPJ association module (RAM) that binds the transcription complex, the nuclear localization 
sequence (NLS), seven ankyrin repeats (ANK), and a proline (P)/glutamic acid (E)/serine (S)/threonine (T) motif 
(PEST) that targets protein for degradation.
B The receptor is activated in a juxtacrine manner through its interaction with a ligand presented by an ad-
jacent cell. An appropriate ligand binding produces a conformational change in the Notch receptor, exposing 
the extracellular domain for ADAM10 enzyme cleavage. After cleavage, there is a second cleavage within the 
transmembrane domain, performed by the gamma-secretase (GS) complex. GS cleavage releases the active 
form of the receptor — Notch intracellular domain (NICD) — into the cytoplasm from which it translocates into 
the nucleus. Here NICD complexes with the DNA-binding transcription activator factor RBPJ (other allies CBF1, 
CSL) to displace the transcriptional repressor Mint. This displacement facilitates the recruitment of activators 
such as Mastermind (MM) and thereby the transcription of pathway target genes. The main targets of the Notch 
pathway are two families of transcriptional repressors: the Hairy and enhancer of split (HES) and the Hairy/
enhancer-of-split related with YRPW motif (HEY) proteins. Although it remains unknown if HES6 is a target of 
Notch pathway, recent studies reveal that HES6 may play an important role in prostate cancer progression. In 
order to quench Notch pathway activation, the NICD is phosphorylated on the PEST domain by E3 ubiquitin 
ligases, thereby targeting it for proteosomal degradation.
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Notch pathway in cancer
The T-ALL link
 Physiologic roles for the Notch pathway were established in the 1920s, but it 
took another 70 years to link genetic alterations that directly activate Notch signal-
ing to cancer. In the 1990s, Ellisen and collaborators (7) found a translocation that 
generated a ligand-independent, autonomously activated form of the Notch receptor 
(NICD) in T-cell acute lymphoblastic leukemia (T-ALL) cells. Bringing together chro-
mosomes 7 and 9, the translocation placed NICD under the transcriptional control of 
T-cell receptor β. By engineering the t(7,9) translocation into transgenic mice, Pear 
and colleagues demonstrated that NICD1 overexpression could cause leukemia (8). 
Data from human patients show that NOTCH1 overexpression correlates with poor 
survival, although it derives only rarely from t(7,9) translocation. Instead, Notch1 ac-
tivation usually occurs through mutations in the receptor that render it constitutively 
active and/or resistant to degradation (9, 10). These and other experiments laid the 
groundwork for Notch signaling became a popular topic in cancer research with the 
ascendance of the idea that embryonic pathways may be reactivated in the develop-
ment of cancer (11–13), and with the identification of Notch pathway expression in 
common solid tumors (Figure 2).
Figure 2 — The number of indexed publications about Notch pathway and cancer continuous increase over the 
last 10 years.
Notch in solid tumors
Mechanisms of Notch activation in Solid Tumors
 Notch signaling can be aberrantly activated in tumor cells through different mecha-
nisms, such as genetic and epigenetic alterations or cross-talk with other oncogenic 
pathways. Over the last decade, several studies showed that DNA alterations can 
activate Notch signaling in a variety of solid tumors. For example, ovary and breast 
cancers have somatic mutations, copy number alterations (14), amplifications (15), 
gene rearrangements (16) implicate Notch pathway members in tumor pathophysiol-
ogy. In addition, histone methylation that regulate the dynamics of gene transcrip-
tion can also induce Notch signaling during tumorigenesis (17). Lastly, Notch can 
also be activated by intracellular cross-talk with other pathways. For example, Notch 
activation in a human B cell leukemia/lymphoma model resulted from induction of 
JAGGED2 ligand by the MYC oncogene (18). Alternatively, Notch activity can be mim-
icked by other transcription factors. For example, hypoxia-inducible transcriptional 
factor 1 alpha (HIF1A) can bypass Notch receptors cleavage by gamma-secretase 
to directly activate Notch-responsive promoters and increase the expression of Notch 
downstream targets (19). Since both Myc and HIF1A have established roles in pros-
tate cancer these alternative routes to Notch activation may play a role in the disease.
Effects of Notch activation in solid tumors
 Once activated, Notch signalling can promote cell growth in a variety of solid tumors 
(Table 1). Of these, breast (mammary gland) cancer has drawn the much attention and 
can serve as one paradigm for understanding the effects of Notch signalling. Activa-
tion of Notch1 in transgenic mice disrupts mammary gland homeostasis — interfering 
with normal expansion, differentiation, and regression programs associated with preg-
nancy and lacation (20). Enforced activation can also induce breast cancer, as shown 
by the oncogenic activity of Notch1 in the mouse mammary gland (20–22). In human 
breast cancers, high levels of JAGGED1 and NOTCH1 proteins have been linked 
to particularly aggressive cancers (23). The poor prognosis seen in these tumors 
may derive from a role for Notch in the development of drug-resistance. In particular, 
Notch signaling levels increase in breast cancer cells that become resistant to the 
estrogen receptor antagonist tamoxifen, the HER2 receptor antagonist trastuzumab 
(Herceptin), and the epidermal growth factor receptor (EGFR) antagonists gefitinib 
and lapatinib (24–27). Within the heterogeneity of breast tumors, there are sub-
populations of cells, called breast cancer stem cells, that are responsible for tumor 
repopulation after chemotherapy and the generation of metastasis (28). Although, 
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breast cancer stem cells are resistant to chemotherapy, recent evidence shows that 
these cells are sensitive to HER2 targeting agents (29,30). Moreover, Notch signaling 
is essential for breast cancer stem cells survival and self-renewal (31–32). Altogether, 
resistance HER2 targeted therapy can be delayed or overcome by combining these 
agents with Notch antagonists (gamma secretase inhibitors), and that effective dosing 
can be attained in vivo. Therefore, Notch antagonism may be useful in treating solid 
tumors that become resistant to targeted therapies, including therapies that target 
endocrine pathways. Given the central role of endocrine therapy in treating prostate 
cancer, this indication deserves further attention.
Notch signaling in the prostate
Notch signaling in prostate development and homeostasis
 During male fetal development, rising androgen levels initiate prostate morphogen-
esis and induce prostate buds to form in the urogenital sinus (UGS) at 10 weeks 
gestation in humans and at embryonic day 17.5 in mice (33–35). Progression from 
the relatively simple UGS to the complex branching structure of the mature prostate 
involves carefully orchestrated patterns of proliferation, invasion, and differentiation. 
During this process, multiple cell-fate decisions are made in both the mesenchyme 
and the epithelium that generate basal, luminal, and neuroendocrine cells, and results 
in zone-or lobe-specific epithelial identity. During early embryonic development, the 
primitive prostatic epithelium is somewhat uniform and cells express markers of both 
basal and luminal cells (36). As the prostate matures, multipotent basal progenitor 
cells differentiate along a basal or luminal phenotype. Both layers contain stem cells 
capable of generating the complete spectrum of basal and luminal cells (37, 38). After 
maturation, the two layers are maintained independently by luminal and basal stem 
cells and transdifferentiation from basal to luminal phenotype is uncommon (39, 40). 
Notably, both populations can be the cell of origin for prostate cancer in mice (38, 39).
 In the prostate, Notch signaling is induced during times of rapid growth corre-
sponding to the formation of the organ in the embryo and its regeneration after 
castration. Whether Notch inhibits or promotes growth in the prostate, is controver-
sial. One of the earliest studies on this topic (41), showed that Notch1 mRNA was 
upregulated in embryonic and postnatal prostate epithelia and dramatically down-
regulated upon maturation of the gland in adulthood. Using a Notch1-GFP trans-
genic mouse in which the activity of a Notch1 gene regulatory region was visualized 
through expression of green fluorescent protein (GFP) the same group attempted 
to further delineate Notch1 expression in the mouse prostate (41). The investigators 
concluded that Notch1 was concentrated in basal cells, however, no clear basal 
Tumor type
Mammary
Ovary cancer
Lung Cancer
Kidney
Head and Neck
Skin
Notch pathway member
JAGGED1 and JAGGED2
NOTCH1 and NOTCH4
NOTCH1 and NOTCH2
JAGGED1, JAGGED2
and NOTCH3
NOTCH1 and NOTCH3
JAGGED1 and NOTCH1
NOTCH1
NOTCH1
Role in tumor biology
Oncogenic
Critical for breast cancer 
tumor progression and bone 
metastasis
In Mouse mammary tumor 
virus models contributed to 
breast tumor cell initiation
Gene rearrangements with 
MAST kinase family members 
confers tumor growth advantage
Somatic mutations and copy 
number alterations important 
for proliferation of ovarian 
cancer cells
NOTCH3 translocation in 
human lung cancers
NOTCH1 promotes tumor cell 
growth and survival through 
regulation of IGF pathway
Pathway is constitutively active 
and promotes growth of renal 
cell carcinoma
Tumor suppressive
Exome sequencing revealed 
NOTCH1 inactivation 
suggesting it may function as a 
tumor suppressor gene
Deletion in keratinocytes 
causes skin cancer through 
microenviroment
References
(84, 85)
(21, 86–88)
(16)
(14, 89)
(90) (91)
(92)
(93)
(94)
Table 1 — A partial list of oncogenic and tumor suppressive effects of several Notch pathway members in 
solid tumors.
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Notch member
Notch1
Notch2
Notch3
Notch4
Jagged1
Jagged2
Delta-like 1
Basal Layer
+
+
-
-
+
+
-
Luminal layer
+
+
+
-
-
-
-
Basal Layer
+
-
-
-
-
-
-
Luminal layer
+
-
-
-
+
-
-
MOUSE HUMAN
expression pattern was demonstrated for Notch1–GFP, and by in situ hybridization, 
Notch1 appeared more luminal than basal. Nevertheless, this study clearly demon-
strated a dynamic expression pattern for Notch1 in prostate epithelium that coincided 
with key phases of organogenesis and epithelial differentiation.
 In mouse adult prostate, the expression levels of the receptors and functional role 
are slightly different from those described during neonatal stage. Both basal and lumi-
nal cells express Notch ligands and receptors (Table 2), but their expression is higher 
in luminal cells and Notch activation induces luminal cells proliferation (42). On the 
contrary, Notch activation in basal cells inhibits proliferation and induces differentia-
tion. Valdez and collaborators identified a positive feedback loop between TGFβ sig-
nals coming from the stroma that activate Notch in basal cells, contributing to inhibit 
proliferation of prostate basal cells and counterbalance androgen growth stimuli.
Table 2 — Expression of Notch ligands and receptor in normal prostate. The expression of other Delta-like 
ligands has not yet been described. The expression of Notch receptors and ligands in each layer is represented 
by (+) and (-) represents the absence of expression.
 Notch signaling was also implicated in the proliferative response of basal cells 
in response to androgen stimulation. Following castration, Notch1 expression rose, 
suggesting a role for the receptor in involution or regeneration (43). Notch inhibition 
through pharmacologic or genetic (Notch1 deletion) means slowed prostate epithe-
lial differentiation while stimulating proliferation, particularly in cells with an “inter-
mediate” phenotype (i.e., those that expressed both basal and luminal cell markers) 
(44). Another mouse model with Rbpj deletion in both basal and luminal cells (42) 
(to impair Notch canonical signaling) found overproliferation of basal cells during 
prostate regeneration in response to androgens. Thus, several studies in mice have 
supported a growth-inhibitory role for Notch in the prostate. 
 Subsequent work (45), in contrast, found that Notch signaling promoted prostate 
growth. Unlike previous studies, this work was performed in adult human prostate 
tissue. In these samples, DLK1, a noncanonical Notch ligand that inhibits Notch sig-
naling, was expressed in basal cells, whereas the NOTCH1 receptor and JAGGED1 
ligand were co-expressed in luminal secretory cells — suggesting that in these hu-
man tissues, the cell types sending and receiving Notch signals were switched in 
relation to the mouse. Using an antibody specific for activated NICD1, Notch signal-
ing activity was detected in endothelial cells lining blood vessels, but not in epithelial 
cells of the quiescent adult prostate. These data indicated that Notch was inactive in 
adult quiescent prostate. However, through expression of NOTCH1, mature prostate 
epithelial cells had the capacity to activate the Notch signaling pathway, whereas 
immature/stem cells used DLK1 to repress Notch activation.
 The investigators confirmed this scenario by studying prostate growth in a hu-
man organ culture model. In growing prostate epithelium, Notch was dramatically 
activated, with downregulation of the Notch inhibitor DLK1, as well as increased 
NOTCH1 and nuclear accumulation of its activated product, NICD1 (45). Importantly, 
as demonstrated by culture with Notch antagonist (gamma secretase inhibitor, or 
GSI), Notch inhibition halted prostate epithelial cell growth (45). 
 Why do the roles of Notch in prostate growth appear to switch polarity from one 
study to the next? Additional work will need to be carried out to answer this question, 
but it seems more likely to be a question of experimental technique. An explanation 
may lie in the use of tissues at different stages of maturation by the different groups. 
One group inhibited Notch in postnatal prostate, at a time when many epithelial cells 
in the prostate had not yet matured. Others used mature prostates in these assays. 
The observed data to date might fit a model in which Notch signaling drives prolifera-
tion and maturation in mature cells, but prevents these processes in immature cells. 
Notch suppresses two central pathways in prostate development and disease: 
Androgen receptor and PI3K/AKT
 Notch interacts with two signaling mechanisms that are central to prostate devel-
opment, growth, homeostasis and carcinogenesis: the androgen receptor (AR) path-
way and the Phosphoinositide 3–kinase (PI3k) / Akt pathway (46, 47). AR signaling is
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sufficient to promote prostate growth and differentiation in the embryo and to support 
glandular homeostasis throughout adulthood. Androgen binding to AR in the cyto-
plasm induces the receptor homodimerization and translocation to the nucleus.
The homodimers bind to the DNA at specific regulatory elements and recruit coacti-
vators (such as Steroid Receptor Coactivator 1 (SRC1) and p300/CBP) to transcribe 
AR target genes (47). Humans with genetic mutations that disrupt AR signaling do 
not develop a prostate and never get prostate cancer (48). In the prostate, AR acti-
vation leads to prostate cancer formation (49) and in advanced cases, AR signaling 
is not only maintained, but it can become promiscuous — triggered by a variety of 
steroid hormones — or even ligand-independent. Thus, signaling by this pathway is 
a cardinal feature of prostate cancers, and interfering with AR signaling is one of the 
first examples of targeted therapy in oncology. 
 A recent study suggested a role for Notch in the acquisition of castration resistance. 
Belandia and collaborators (50) observed that the Notch target HEY1 directly bound 
the N-terminal activation domain of AR, suppressing androgen signaling. NICD also 
suppressed AR activity, was active in cells with different origins — myoblasts, pros-
tate and breast cancer — and suppressed AR activity more effectively than HEY1 
alone. The latter effect occurred most likely as a consequence of the induction of 
related transcriptional repressors, such as HES1 (50). In contrast to these in vitro 
interactions between Notch and AR, the real process in the prostate may be more 
complex. Using immunohistochemistry, strong nuclear HEY1 staining was observed 
in benign prostate hyperplasia, but in prostate cancer this transcription factor local-
ized only to the cytoplasm, indicating reduced nuclear activity of HEY1 in cancer 
and supporting the idea that cancers downregulate Notch signaling (50). In the 
same study, however, AR always localized to the nucleus in both benign and malig-
nant tissues (50). Thus although HEY1 has the ability to inhibit AR signaling when 
expressed at high levels in cell lines, in actual human cancers, HEY1 appeared to 
be excluded from the nucleus, leaving AR free to transcribe its target genes. 
 PI3K/AKT activates growth and migration in the prostate (51,52). This pathway is 
triggered when G protein-coupled or tyrosine kinase receptors activate PI3–Kinase. 
Then, PI3K phosphorylates cell membrane proteins necessary for AKT binding so 
it can also be phosphorylated by its activating kinases. PI3K/AKT signaling is sup-
pressed by the phosphatase activity of the Phosphatase and tensin homolog (PTEN), 
an important tumor suppressor gene. Deletions in PTEN gene and consequent de-
regulation of PI3k/mTOR signaling contribute to malignant transformation of prostate 
cells in vitro and in mice models and are common features of advanced human pros-
tate cancers (53–55). Whelan and colleagues (56) found decreased expression of 
Notch1 in prostate cancer compared with benign prostate and further observed that 
NICD1 directly induced PTEN expression, resulting in diminished PI3K/AKT activity. 
These data suggest the possibility of a tumor suppressive effect of Notch signaling, 
particularly when triggered by Notch1. 
 Interestingly, a reciprocal feedback mechanism has been recently described that 
links the PI3/AKT and AR pathways. Carver and collaborators (57) recently found 
that suppression of either pathway induces activity in the other. Thus, inactivation of 
PI3K/AKT lead to increased AR activity, whereas suppressing AR lead to increased 
PI3K/AKT. It is well established that PI3K/AKT signaling increases in advanced pros-
tate cancer (58). Thus one might expect that decreased Notch signaling permits this 
increase in PI3/AKT in prostate cancer. 
Notch signaling in prostate cancer
Notch pathway expression and function in prostate cancer cell lines
 In prostate cancer, there is good agreement between various studies on the 
expression of Notch components in prostate cancer cell lines. However, the func-
tional significance of Notch signaling in prostate cancer is controversial. Studies 
from different laboratories consistently detect high level constitutive expression of 
NOTCH1 and NICD1 in all of the frequently studied human prostate cancer cell lines 
(PC3, DU145, 22Rν1, and LNCaP) (41, 59). In these cells, knockdown of NOTCH1 
levels by small interfering RNA can suppress malignant properties, including cell 
invasion (59), survival, and proliferation (60). The latter result was surprising, given 
that earlier work had shown that Notch pathway activation, as achieved through 
engineered overexpression of NICD, had a similar growth inhibitory effect (41). One 
possible reason for both inhibition and activation of the pathway to inhibit growth is 
that Notch pathway activation could have different effects at different levels, a so 
called “Goldilocks effect.” Moderate Notch signaling could support growth whereas 
extreme levels of pathway activity (high or low) may inhibit growth. Another potential 
contributor to different laboratories having different results stems from the vagaries 
of research using cultured cells. In particular, calcium levels vary significantly in 
different commonly used culture media components and can have dramatic effects 
on epithelial cell growth and differentiation (61). High levels of calcium can promote 
cell autonomous Notch receptor cleavage, producing the active NICD form with 
little or no contribution of ligand presentation by adjacent cells (62). These results 
indicate the need for additional studies that carefully titrate levels of Notch signaling 
while controlling for calcium levels and culture conditions. Until then, the roles of 
the pathway in prostate cancer are likely to remain controversial. In the meantime, 
examining research done on prostate cancer tissues might provide some insight.
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Expression of pathway components in prostate cancer tissue
 Most studies demonstrate an upregulation of Notch pathway members in pros-
tate cancer compared to benign tissue. In the TRansgenic Adenocarcinoma of the 
Mouse Prostate (TRAMP) model, Notch1 mRNA levels rose upon metastasis to 
regional lymph nodes (41), suggesting a role for the pathway in metastasis. In hu-
mans, an analysis of mRNA expression databases showed decreased mRNA levels 
of NOTCH1 and HEY1 in prostate cancer compared to benign glands (44). Studies 
focusing on protein levels, in contrast have found increasing levels of Notch pathway 
members in human cancers along the progression spectrum. Using immunohisto-
chemistry, Bin Hafeez and collaborators found that levels of NOTCH1 protein in-
creased with increasing Gleason grade (59). Their finding that NOTCH1 levels were 
particularly high in cancer cells surrounding capillaries provided further support to 
the idea that Notch signaling might enhance the ability of such cells to escape into 
the bloodstream and metastasize. Indeed, when compared to localized tumor or 
benign tissue, metastases showed distinctly elevated levels of JAGGED1 protein 
(63). Intriguingly, tumors with highest levels of JAGGED1 were least likely to be 
cured by radical prostatectomy, suggesting that JAGGED1 contributes to the ability 
of these cancers to metastasize prior to surgery. Thus, bearing in mind contradictory 
evidence in mice (41), the preponderance of evidence supports upregulation rather 
than downregulation of Notch components with human prostate cancer progression. 
While far from proof, this increased level of pathway expression is consistent with 
a functional role for Notch in prostate cancer progression. Approaches to further 
explore Notch function in this disease could include conditional knockout of Notch 
pathway members in mouse models of prostate cancer and trials of Notch antago-
nists in prostate cancer-bearing mice and humans (see below).
Notch pathway members distinguish high grade from low grade prostate 
cancers and serve as biomarkers to improve biopsy accuracy 
 When considering the potential function of any signalling pathway in prostate can-
cer, it is useful to do so in the context of Gleason Grade. In particular, it is only Gleason 
grades of 7 and above that have the potential to metastasize and kill (64, 65). Thus, 
when properly evaluated (i.e., through comprehensive examination of a surgically 
removed prostate gland), the Gleason grade accurately distinguishes between in-
dolent aggressive prostate cancers. Unfortunately, biopsies often do not accurately 
distinguish indolent cancers from their more aggressive counterparts (66, 67), leading 
to frequent “overtreatment” of cancers that do not warrant treatment. At the other 
end of the spectrum, high grade tumors can rapidly recur after treatment and kill 
patients regardless of primary treatment. New evidence suggests that members of 
the Notch pathway are distinctive features of aggressive prostate cancers with high 
Gleason grade. For example, comparing gene expression profiles from purely high-
grade (Gleason 4+4=8) vs. purely low grade (Gleason 3+3=6) microdissected cancer 
cells, Notch signaling was the foremost distinguishing feature. This observation was 
confirmed in a meta-analysis using gene profling data form other labororaties. In par-
ticular, cancer cells with metastatic potential (Gleason 4+4=8) upregulated the Notch 
ligand JAGGED2, the NOTCH3 receptor, and the potential Notch target gene, Hairy 
enhancer of split family member, HES6 (68, Filipe LF Carvalho and David Berman, 
submitted) (Figure 3). Thus, a particular Notch ligand, receptor, and response gene, 
appeared to distinguish aggressive prostate cancers. The arrangement of these com-
ponents into a potential signaling cascade suggests that the pathway is functional in 
aggressive prostate cancers. 
 These findings raise new questions regarding potential uses of Notch pathway mem-
bers as diagnostic and therapeutic targets in prostate cancer. One such question is 
whether Notch signalling might be a useful drug target in aggressive prostate cancers.
Figure 3 — Schematic representation of possible Notch signaling dynamics in prostate benign glands and 
cancer cells.
BENIGN CANCER
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Notch pathway inhibitors
Gamma-Secretase inhibitors
 The most widely used compounds to inhibit Notch pathway are gamma-secretase 
inhibitors (GSI). These drugs were initially developed in an effort to reduce amyloid–β 
protein aggregates in Alzheimer’s disease. GSIs were subsequently found to be an 
attractive candidate treatment method for cancers involving active Notch signaling. 
Initially tested in T-ALL lines and later in prostate, breast, and lung cell lines and xeno-
grafts, GSI treatment was found to result in growth suppression (10, 24, 60, 69, 70). 
In early mouse studies it quickly became evident that these drugs caused toxicity in 
other Notch-dependent tissues, particularly the gastrointestinal tract and the thymus 
(71, 72). However, alternative dosing strategies have been found to limit this toxicity. 
For example, intermittent dosing, as well as co-administration of dexamathosone 
have been shown to reduce gastrointestinal toxicity in animals exposed to GSIs 
without compromising anti-tumor effects (73, 74). 
Selective Notch inhibitors
 More precisely targeted approaches have emerged to effectively shut down the 
Notch pathway. By focusing on individual ligands or receptors, these agents have the 
potential to avoid side-effects associated with pan-Notch inhibition (75). Antibodies 
binding the receptors Notch1 and Notch2, and the ligand Delta-like 4, have been used 
experimentally and shown to inhibit cancer cell proliferation with minimal intestinal 
toxicity (76, 77). These approaches rely on cancer cells having relatively more strin-
gent requirements for the targeted ligand or receptor compared to intestinal entero-
cytes. A second approach utilized synthetic peptides that inhibit Notch1 from engaging 
the transcriptional machinery. Stabilized alpha-helical peptides have been produced 
that can specifically block NICD1 binding to RBPJ. Used in vivo in a Notch1 driven 
mouse leukemia model, these peptides repressed Notch1 target gene expression and 
leukemegenesis while avoiding gastrointestinal toxicity (78). This agent could have 
lower toxicity than GSIs because it does not affect signaling by other Notch recep-
tors (Notch2, 3, or 4), or because it spares other GSI targets outside of the Notch 
pathway. Ultimately, it will be critical to explore whether cancer cells and enterocytes 
have differential requirements for signaling by each of the 4 Notch receptors. These 
differential requirements may form the basis for enhancing the therapeutic index of 
strategies to more safely and effectively target Notch signaling.
Clinical trials with Notch inhibitors
 There are currently twenty-eight clinical trials registered at the NIH recruiting pa-
tients to study the effects of Notch inhibitors, mainly GSI, in cancer. Among these 
trials, there is one specific for prostate cancer patients: it combines the anti-androgen 
bicalutamide with a GSI in patients whose cancers recur after surgery (prostatec-
tomy) or prostate radiation. There are another seven trials recruiting patients with 
unspecified metastatic solid tumors that can enroll patients with prostate cancer. 
Results from two Phase I clinical trials with escalate doses of GSI recently published 
reported that these drugs were well tolerated and there was potential clinical benefit 
in brain tumor (glioma), colorectal adenocarcinoma and melanoma patients (79, 80). 
No benefits, however, have been reported for prostate cancer patients. As mentioned 
above, the lack of consistent experimental data about the role of Notch on prostate 
cancer makes it difficult to predict the therapeutic effects of GSIs or to pinpoint the 
types of patients that will benefit most from these drugs. A better understanding of 
differential activities of individual Notch ligands and receptors — within the pathway 
and in interactions with other pathways — will reveal whether these drugs should be 
added to the therapeutic armamentarium of prostate cancer and how best to do so.
Conclusion
 Evidence increasingly supports the notion that the Notch pathway interacts with 
many different signaling cascades to regulate critical cellular processes. In the pros-
tate, there is evidence that Notch is important for the normal development of the 
gland and that its deregulation may be involved in tumorigenesis. It remains unclear 
whether the pathway stimulates or inhibits prostate cancer progression. Thus, de-
spite the emergence of effective and non-toxic inhibitors of Notch signaling, it is 
not currently clear what to expect when these agents are used in prostate cancer 
patients. Future studies should clarify this important issue. In the meantime, the 
pathway appears to be upregulated in more aggressive prostate cancers compared 
to indolent cases. This differential expression pattern could be exploited in selecting 
patients who need treatment as opposed to those that can be maintained in active 
surveillance programs.
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RATIONAL AND AIMS
 A major drawback of prostate-specific antigen (PSA) screening is the diagnosis 
and overtreatment of indolent prostate cancer. Therefore it is necessary to find new 
biomarkers and pathways that better distinguish indolent from lethal prostate cancer. 
Microarray gene expression studies showed that in high grade localized prostate 
cancer one of the most overexpressed signaling cascades is the Notch pathway. 
Among all the members of Notch pathway, Hairy enhancer of Split 6 (HES6) was the 
most upregulated in tumors with lethal potential (high-grade tumors). Thus, one of 
the aims of this research project was to understand the molecular mechanisms and 
interactions of HES6 in prostate cancer that may contribute to its aggressiveness 
and progression. 
 Due to my medical background and a career goal to establish as an independent 
physician-scientist in urology, I was excited by the idea of working on new predictive 
and prognostic markers. As mentioned before, PSA screening of prostate cancer 
results in overdiagnosis of indolent tumors and consequently overtreatment with 
important adverse effects, such as incontinence or erectile dysfunction. So an op-
tion to manage tumors with low grade features, called Active Surveillance, is to per-
form intermittent digital rectal exams and prostate biopsies with the intent to avoid 
treatment until the cancer progresses. While I evaluate the contribution of Notch 
signaling for tumor progression, we also evaluated the potential of established as-
says as biomarkers guiding active surveillance. One particularly promising assay is 
the expression of the tumor suppressor Phosphatase and tensin homolog (PTEN) 
protein in prostate biopsies. The question we addressed was whether the loss of 
PTEN can distinguish the tumors that will upgrade and need treatment from those 
who can be managed on active surveillance. 
 When prostate cancer cells metastasize to bone, 3⁄4 of the patients die within a 
period of 5 years. Due to the lack of good tissue resources during the progression 
of prostate cancer, the molecular events that contribute to metastasis development 
and treatment failure are largely unknown. To address this problem and as a plat-
form on which to study Notch and other potential mediators of the lethal phenotype, 
we developed experimental systems that without relying in cell surface markers, 
isolated viable circulating tumor cells (CTCs). To test CTCs tumor-forming ability, 
we xenografted CTCs, from the Transgenic Adenocarcinoma of the Mouse Prostate 
(TRAMP) mice and from patients with late-stage prostate cancer, into immunodefi-
cient mice. This approach allowed us to determine that viable CTCs contain tumor-
initiating cells.
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Figure 1 — Schematic representation of prostate cancer progression. The aims of this thesis address differ-
ent stages of prostate cancer. The length of the black boxes indicates the period focused by each aim during 
cancer progression.
 Therefore, the major goal of this doctoral project was to understand the molecular 
and cellular characteristics of prostate cancer cells with lethal potential and provide 
reliable markers to ameliorate clinical decisions. 
Specifically, the aims of this project were:
1 Notch signaling pathway as modulation of prostate cancer aggressiveness 
• Characterize the expression of all canonical Notch pathway components in 
benign and cancer prostate cells. 
• Determine the responsiveness of Notch receptor and main targets to androgen 
stimulation. 
• Evaluate the response of prostate cell lines to Notch pathway blockade with a 
gamma-secretase inhibitor.
• Identify the molecular pathways controlled by HES6 in prostate cells. 
• Using in vitro cellular assays, analyze HES6 contributions for cancer progression. 
2 PTEN as a molecular marker to predict upgrading of prostate cancer from 
biopsy to radical prostatectomy
• Determine whether loss of PTEN protein expression can improve the selection 
criteria of prostate cancer patients to active surveillance.
3 Proving and harnessing the biological activity of circulating prostate 
cancer cells
• Without relying on cell size or the expression of differentiation markers, isolate 
viable prostate CTCs from mice and humans.
• Generate xenografts using circulating tumor cells in immunodeficient mice to 
assay their ability to initiate new tumors.
PTEN loss as a predictor of Gleason score upgrading (Aim #2)
Notch pathway an HES6 as modulators of prostate cancer aggressiveness (Aim #1)
Biological activity of circulating tumor cells (Aim #3)
CHAPTER 3 —
METHODS
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METHODS
 This section describes the methods that successfully generated data presented in 
the following chapters. I divided the methods according to the chapters where they 
were used to smoother the reader’s pilgrimage throughout this section.
Chapter 4
Materials and Methods
Plasmids, virus and construct generation HES6 (clone LIFESEQ7399489, 
Open Biosystems) was subcloned into the lentiviral vector pNL-EGFP/CMV-
WPREdU3 to establish overexpressing stable cell lines. shRNAs targeting 
HES6 mRNAs were obtained from the Expression Arrest-TRC shRNA Libraries 
(TRCN0000017828). Notch3 intracellular domain construct (gift from Dr Nicolas 
Gaiano) was subcloned into pcDNA 3.1(-) (Invitrogen). The vectors used in dual-
luciferase reporter assay experiments were CBFRE-luc (Addgene #26897) and 
pGL2 (Promega). 
Cell lines and cell culture Human cancer cell lines were obtained from the Ameri-
can Type Culture Collection and maintained in RPMI 1640 (Gibco) supplemented with 
10% fetal bovine serum (FBS) and Penicillin-Streptomycin (Invitrogen), except VCaP 
and LnCaP96. VCaP were provided by Dr William B. Isaacs (Brady Urological Institute, 
The Johns Hopkins University School of Medicine) and maintained in DMEM/10% 
FBS (Gibco) and LnCaP96 cells were a gift from Dr Alan K. Meeker (Brady Urological 
Institute, The Johns Hopkins University School of Medicine) generated by long-term 
culture of LnCaP in charcoal-stripped FBS. Prostate epithelial cells RWPE–1 and 
PrEC were cultured according to vendor’s instructions. All cell line identities were 
confirmed by forensic identity analyses within 6 months of use. For the androgen 
withdrawn experiments, LnCaP cells were washed with charcoal-stripped FBS three 
times for 1h and incubated in 10% charcoal-stripped FBS containing medium for 48h 
before stimulation with 10nM of dihydrotestosterone (DHT). 
Real-time PCR analysis Total RNA was isolated with RNeasy Mini kit (Qiagen) 
and cDNA was synthesized with 1 mg of total RNA using High-Capacity cDNA Re-
verse Transcription kit (Applied Biosystems). cDNA was amplified on a StepOne Plus 
(Applied Biosystems) using TaqMan gene-specific oligonucleotide primers or custom 
designed primers (Supplementary Table S1). To determine the genes differentially 
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expressed in cancer and benign cell lines, we designed Taqman gene plates compris-
ing all Notch pathway members described in mammals and five housekeeping genes. 
Results are presented as a heatmap using Euclidean distance and ward linkage for 
clustering using median centered delta CT values for each gene.
Immunoblotting Protein lysates in NuPAGE buffer (Invitrogen) were sepa-
rated by gradient 4–12% BisTris Gel and transferred to polyvinylidene difluoride 
membrane. Primary antibodies used were rabbit monoclonal anti-Notch1 (D1E11; 
1:1000; Cell Signaling), rabbit polyclonal anti-cleaved Notch1 (Val1744; 1:1000; 
Cell Signaling), rabbit monoclonal anti-Notch2 (8A1; 1:1000; Cell Signaling), rab-
bit polyclonal anti-Notch3 (Pro2311; 1:1000; Cell Signaling), rabbit polyclonal anti-
HES1 (ab71559; 1:1000; Abcam), rabbit polyclonal anti-HEY1 (ab22614; 1:500; 
Abcam), rabbit polyclonal anti-HES6 (ab66461; 1:1000; Abcam), mouse mono-
clonal anti-glyceraldehyde–3–phosphate dehydrogenase (GAPDH) (clone 6C5; 
1:1000; Santa Cruz Biotechnology). The membrane was incubated sequentially 
with primary antibodies (overnight at 4oC), horseradish peroxidase (HRP)-conju-
gated anti-rabbit or anti-mouse and chemiluminescent substrate (Thermo Fisher) 
before exposure to film. 
Luciferase reporter assay Cells were plated in 24–well plates and 24 hours 
later transfected using Lipofectamine2000 (Invitrogen) with pGL2 (control) or with 
CBFRE-luc to determine endogenous Notch pathway activity in prostate cells. After 
48 hours, luciferase activity was determined using Dual-Luciferase Reporter Assay 
system (Promega) and normalized to PrEC basal luminescence. All experiments 
were performed in triplicate. 
siRNA transient knockdown Notch3 siRNA (Supplementary Table 2) transient 
transfections (final concentration of 10 nmol/L) were carried out by using Lipo-
fectamine 2000 (Invitrogen), following the manufacturer's instructions. Nontargeting 
siRNA was used as a control. Cells were lysated for western blot 24 hours after 
siRNA transfection. 
DAPT treatment and IC50 assay 24 hours after seeding the cells, gamma secre-
tase inhibitor N-[N–(3,5–Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
(DAPT) was added to 200 ml of growth media per well in final concentrations rang-
ing from 1 nmol/L to 400 mmol/L. Viability was assayed (see below) after 96 hours. 
The half maximum inhibitory concentration (IC50) of DAPT was calculated using 
GraphPad Prism software.
Cell viability and proliferation assays 22Rv1 and LnCaP with stable shRNA 
HES6 knockdown or PC3 stably overexpressing HES6 were seeded (500 cells per 
well) in 96–well black flat-bottom tissue culture plates. Cell viability and growth was 
determined using Alamar Blue vital dye (Invitrogen) according to the manufacturer’s 
instructions. Values were reported as mean standard error of optical density of trip-
licate wells fro each concentration and time point. 
Immunohistochemistry and Immunofluorescence IHC and IF staining were 
performed as described previously (1, 2) using anti-Hes6 antibody (ab66461; 
1:1000; Abcam). Mann-Whitney test used for statistical analysis of HES6 staining 
intensity was measured automatic quantitative analysis. 
Androgen-deprived tissue in tissue microarray (TMA) We used a previously 
described TMA comprising formalin-fixed paraffin-embedded prostate cancer tissue 
from (n=55) patients treated with androgen-deprivation therapy prior to prostatec-
tomy and from (n=12) untreated controls (3). 
Invasion assays 22Rv1 or LnCaP cells infected with control or shHES6 lentiviruses 
(see plasmids and viruses above) were seeded at 7.5 x 104 cells/well or 5 x 104 PC3 
cells infected with control or HES6 overexpression lentiviruses. The assay was per-
formed in triplicate and in two independent experiments as previously described (4). 
Student t test was used to evaluate significant differences and a statistical significance 
was considered at p < 0.05.
Colony-forming efficiency assay Colony-forming efficiency assays were con-
ducted as described earlier (5). All visible were counted and results presented as 
total number colonies stander error in two individual experiments. 
Gene expression arrays and data analysis Differential gene expression analysis 
was performed as previously described (6–8), using statistical packages from the R/
Bioconductor project (9, 10). Briefly, gene expression was measured on the Illumina 
HT–12 v4 whole genome gene expression microarray. For each individual microar-
ray feature a generalized linear model was fit to estimate expression differences 
between groups. Moderated t-statistics were obtained by empirical Bayesian shrink-
age of log2 fold-change standard errors (11), and adjustment for multiple testing was 
obtained using the Benjamini and Hochberg method (12). Gene annotation for the 
microarray used in this study was obtained from the corresponding R-Bioconductor 
metadata packages.
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Chapter 5
Patients and tissue samples
 After obtaining institutional review board approval, the Johns Hopkins Hospital 
(JHH) Pathology database was queried for all needle biopsies performed at JHH or 
Johns Hopkins Bayview Medical Center (BMC) that contained only Gleason Score 
3+3=6 (GS 6) tumor followed by a radical prostatectomy (RP) specimen that con-
tained GS > 6 tumor occurring between 2000–2011. Controls with GS 6 tumor on 
biopsy followed by only GS 6 tumor on RP were selected from sequential biop-
sies occurring between 2000–2004 at JHH and 2000–2011 at BMC. Patients who 
underwent any neoadjuvant therapies (hormonal therapy, radiation therapy) were 
excluded. As is routine at JHH and BMC, all RP specimens were entirely submitted 
and processed for histologic analysis. All biopsies and RP slides were re-reviewed 
and re-graded by trained uropathologists using the 2005 modified International 
Society of Urologic Pathology (ISUP) grading system. Each case was assigned a 
primary, secondary and tertiary (for RP specimens) Gleason pattern. Cases where 
the slides were not available for re-review and cases with biopsy GS > 6 on re-
review were excluded from the analysis. A single block (generally consisting of two 
needle biopsy cores) containing the largest percentage involvement by tumor was 
selected for PTEN immunostaining (described below). In order to assure that there 
was enough tumor available for reliable evaluation, cases with less than 5% tumor 
involvement on any single needle core were excluded.
Clinico-pathologic parameters
 Clinical parameters were extracted from the Johns Hopkins Brady Urological 
Institute database and included age, race where available (white vs. non-white), 
pre-operative serum prostate-specific antigen (PSA) measured closest to time of 
biopsy, and clinical stage. PSA density was calculated by dividing the pre-operative 
PSA by the prostate gland weight at radical prostatectomy. PSA recurrence was 
defined as a serum PSA level >0.2 ng/mL following RP. Pathologic parameters 
were extracted for each case from the Johns Hopkins Department of Pathology 
database and included the total number of needle cores sampled, the absolute 
number of cores involved by tumor, the percent tumor present on the maximally 
involved core, the presence of tumor on bilateral cores (right and left) and the pres-
ence of perineural invasion. The fraction of cores involved by tumor was calculated 
by dividing the number of involved cores by the total number of cores sampled in 
each case. 
PTEN Immunohistochemistry
 4 µm biopsy sections were deparaffinized and re-hydrated under standard con-
ditions. Antigen unmasking was performed by steaming in EDTA buffer (pH 8.0) 
for 45 minutes. Endogenous peroxidase activity was quenched by incubation with 
peroxidase block for 5 minutes at RT. Slides were incubated for 45 minutes at room 
temperature with a rabbit anti-human PTEN antibody (Clone D4.3 XP; Cell Signal-
ing, Danvers, MA; 1:50 dilution). A horseradish peroxidase-labeled polymer (Power-
Vision, Leica Microsystems, Bannockburn IL) was applied for 30 minutes at RT and 
signal detection was performed using 3,3'–diaminobenzidine tetrahydrochloride 
(DAB) as the chromagen. Slides were counterstained with hematoxylin, dehydrated, 
and mounted.
IHC interpretation
 PTEN IHC on each case was independently scored by two uropathologists using 
a previously validated dichotomous scoring system. Cases were considered to have 
PTEN protein loss if the intensity of cytoplasmic staining was markedly decreased 
or entirely negative across >10% of tumor cells compared to surrounding benign 
glands and/or stroma. In cases where the two scoring uropathologists disagreed 
about the PTEN IHC scoring (17/174 or 10% of total), a third uropathologist blindly 
scored the case to break the tie.
PTEN FISH
 A four-color FISH method was designed based on methods used previously. As 
described, FISH analysis was performed on needle cores using adjacent sections 
stained with DAPI (40,6–diamidino – 2–phenylindole, dihydrochloride) in selected 
areas of tumor with PTEN loss by immunohistochemistry. H&E needle cores sec-
tions were scanned digitally and available for side-by-side comparison with the 
FISH images to confirm delineated marked regions of interest. PTEN copy number 
was evaluated by counting spots for each probe in 50 non-overlapping, intact, 
interphase nuclei per case. In cases where the PTEN status was inconclusive, 
100 cells were evaluated. Variation of nuclear size in tumor cells required the use 
of non-PTEN-deleted prostate cancer cores as controls to define the threshold for 
classifying the PTEN copy number. Overall, the mean + 3 standard deviations was 
used as the cutoff value for assigning hemizygous deletion status in each case. 
This approach was particularly useful for cores exhibiting more cellular heteroge-
neity where cells differed in shape, size or density. Homozygous deletion status 
for PTEN was defined by more conservative criteria, a simultaneous lack of both 
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PTEN locus signals in 30% of scored nuclei. Background information on the assay, 
cell selection criteria and on determining cut-off thresholds is also available on the 
website (www.ptendeletion.net).
Statistical analysis
 Means and proportions of characteristics of cases and controls were compared 
using the two-sample t-test and the chi-square test, respectively. Multivariable lo-
gistic regression was used to estimate the odds ratios (ORs) and 95% confidence 
intervals (CI) of a biopsy upgrade among men with markedly decreased PTEN. 
First, ORs were estimated adjusted for age at diagnosis. Next, results were adjust-
ed for preoperative PSA (continuous, log-transformed) and clinical stage (binary, 
T2 or higher). Results were further adjusted for race (binary, nonwhite). Statistical 
analyses were performed using SAS 9.3 (Cary, NC).
Chapter 6
Patient selection for CTCs collection
 Patients treated at the Johns Hopkins Sidney Kimmel Comprehensive Cancer 
Center (Baltimore, MD) with castration-resistant PCa and radiologic evidence of 
distant osseous or soft tissue metastatic disease were recruited according to an 
institutional review board (IRB)-approved protocol. All patients signed a written in-
formed consent. A total of 14 patients (Table 1, CHAPTER 6) donated 7 mL of blood 
on one or more occasions for CTCs immunocytochemistry or xenograft. Blood from 
healthy individuals without evidence of PCa was spiked with DU145 cells.
Cell Culture
 Human DU145 and LnCaP prostate cancer cells were obtained from the Ameri-
can Type Culture Collection, maintained in RPMI 1640 media (Gibco) supplemented 
with 10% fetal bovine serum (Gibco) and Penicillin-Streptomycin (Invitrogen).
Cell isolation
 Blood drawn into a heparinized tube followed two different approaches (Fig. 1 
and 4, CHAPTER 6) to remove red blood cells and collect nucleated cells: red 
cell lysis or density gradient centrifugation. After red cell removal, nucleated cells 
present in blood were collected, incubated with anti-leukocyte antibody CD45 
magnetic microbeads (Miltenyi Biotec), placed into magnetic depletion columns 
(Miltenyi Biotec) to deplete white blood cells and all tumor cells that flow through 
the columns were collected for further studies. As a “proof-of-principle” for isolation of 
viable circulating cells, human DU145 prostate cancer (1 x 106) cells were spiked 
in blood from healthy individuals and placed back in culture for 48 hours to moni-
tor if the cells were viable and able to expand in culture. CTCs from PCa patients 
were either spread across microscopic slides for immunofluorescent analysis or 
xenografted in mice.
Generation of CTC xenografts and determination of engraftment with PSA
 CTCs from both TRAMP mice and human prostate cancer patients were in-
serted into anesthetized male highly immunodeficient NOD.Cg-Prkdcscid Il2rgtm-
1Wjl/SzJ mice (Figure 1 and 4, CHAPTER 6), also known as NOD SCID gamma 
(NSG) mice (13). NSG mice lack functional T cells, B cells, and NK cells and have 
markedly reduced dendritic cell and macrophage activity. This high degree of im-
munodeficiency results in superior engraftment of human cells (14).
 Approximately 700 mL of blood from TRAMP mice (n=9) went through the red cell 
lysis step and nucleated cells were afterwards injected into the tail vein of NSG mice. 
To confirm the existence of CTCs in TRAMPs blood, we spread TRAMP nucleated 
cells in a microscope slide and performed Wright's stain.
 CTCs isolated from PCa patient blood were injected into the tail vein of NSG 
mice (n=4) or wrapped in mouse newborn seminal vesicle mesenchyme (SVM) and 
inserted under the renal capsule (n=7) as described previously (15). Briefly, this 
technique consists in the isolation of SVM from newborn (day 0) C57BL/6 mice (15), 
1 x 105 SVM cells were combined with CTCs isolated from patients in a matrigel 
(BD Biosciences) disk. The disk, containing CTCs and the SVM were combined 
and cultured 12 hours in RPMI supplemented with 1 mM of dihydrotestosterone, 
and then introduced under the renal capsule. To confirm the capacity of SVM to 
support prostate epithelial growth, benign primary mouse prostate epithelial cells 
( 1 x 106 ) were combined with SVM and also grafted under the kidney capsule. 
PSA-producing cancer cells LnCaP ( 1 x 106 ) cells were also used as controls, to 
confirm that the grafting conditions supported human prostate cancer growth and to 
confirm the performance of ultrasensitive PSA tests (see below) on mouse serum. 
Since mice do not make PSA, human CTC engraftment was monitored monthly by 
ultrasensitive nano-PSA assays (Nanosphere Inc, Chicago, IL) performed on serum 
prepared from 50 mL of mouse blood (16). NSG mice injected with TRAMP CTCs 
were euthanized 3 months after grafting, and the NSGs grafted with human circulat-
ing cells were euthanized 8 months after grafting. An expert veterinary pathologist 
performed comprehensive necropsies as well as histologic examination of the liver, 
lungs, spleen and the grafts from all animals.
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Immunohistochemistry and immunofluorescence
 Formalin-fixed, paraffin-embedded tissue samples from the liver, lungs, spleen and 
CTC xenografts were sectioned (4 mm) and immunohistochemistry was performed as 
described using anti-SV40 T-Ag (clone Pab101 Santa Cruz, 1:1000) or anti-androgen 
receptor (clone N–20 Santa Cruz, 1:500) antibodies for immunodetection.
 Immunofluorescent staining for cytokeratin 8 (1:500; clone M20 Abcam) and 
EpCAM (1:500; clone VU–1D9 Abcam) was performed to confirm the collection 
of CTCs from castration-resistant PCa patients. Cells obtained after CD45 deple-
tion were spread onto a microscope slide, stained as previously described and 
analyzed under a 100x oil immersion objective using a Nikon E400 fluorescence 
microscope (Nikon).
PART II — RESULTS
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Abstract
 
 Notch signaling is implicated in the pathogenesis of a variety of cancers, but its 
role in prostate cancer is poorly understood. However, selected Notch pathway 
members are overrepresented in high-grade prostate cancers. We comprehensively 
profiled Notch pathway components in prostate cells and found prostate cancer-
specific upregulation of NOTCH3 and HES6. Their expression was particularly high 
in androgen-responsive lines. Notch stimulation in these cells induced canonical 
Notch targets, HES1 and HEY1. We found that androgen stimulation also induced 
HES and HEY protein family members HES1 and HEY1, which are well known 
canonical targets of Notch signaling. Androgen simultaneously suppressed Notch 
receptor expression, suggesting that androgens can activate Notch target genes 
in a receptor-independent manner. Using a Notch-sensitive RBPJ reporter assay, 
we found that basal levels of Notch signaling were significantly lower in prostate 
cancer cells compared to benign cells. Accordingly pharmacological Notch pathway 
blockade did not inhibit cancer cell growth or viability. In contrast to canonical Notch 
targets, HES6, a HES family member known to antagonize Notch signaling, was 
not regulated by Notch signaling, but relied instead on androgen levels, as we were 
able to demonstrate both in culture and in human patients. When engineered into 
prostate cancer cells, reduced levels of HES6 resulted in reduced cancer cells inva-
sion and clonogenic growth. By molecular profiling, we identified potential roles for 
HES6 in regulating hedgehog signaling, apoptosis, and cell migration. These results 
contraindicate an oncogenic role for Notch signaling in the prostate, but implicate 
HES6 as a protagonist in prostate cancer progression.
Introduction
 Prostate-specific antigen (PSA) screening has vastly improved detection of pros-
tate cancer at an early, curable stage (1, 2). However, early detection with PSA has 
resulted in overtreatment of harmless low-grade cancers (3). Only men with ag-
gressive cancers are likely to derive any survival benefit from treatment (4). Safely 
addressing overtreatment in prostate cancer will require a more sophisticated un-
derstanding of pathways that distinguish indolent prostate cancers that do not merit 
treatment from those that are potentially harmful. Recent mRNA profiling studies 
have revealed molecular features that may aid in this distinction, including the Hairy 
and Enhancer of Split transcriptional repressor, HES6 and other members of the 
Notch pathway (5, 6). Here, we intensively investigate Notch pathway expression in 
prostate cancer and further investigate HES6 regulation and function.
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 The Notch signaling pathway is composed of four receptors Notch1 through 
Notch4, and five ligands Jagged 1 and 2 (JAG1 and JAG2) and Delta-like 1, 3, 
and 4 (DLL1, DLL3, DLL4). Ligand bound to the surface of a neighboring cell binds 
to the Notch receptor, inducing a conformational change that facilitates cleavage 
by the γ-secretase complex. γ-secretase cleavage releases the active form of the 
receptor — Notch intracellular domain (NICD) — into the cytoplasm. Cytoplasmic 
NICD translocates into the nucleus to complex with the DNA-binding transcriptional 
co-activator RBPJ. The resulting NICD/RBPJ complex activates Notch target genes, 
which include two families of transcription repressors: Hairy and enhancer of split 
(HES) and Hairy/enhancer-of-split related with YRPW motif (HEY). Expression of 
these repressors, particularly HES1 and HEY1, are used to monitor Notch pathway 
activation. In addition, there is increasing evidence for regulatory feedback loops 
between HES family members. One member, HES6, is of particular interest, be-
cause it is preferentially expressed in aggressive prostate cancers (6), and its status 
as a member of the Notch signaling pathway is not well understood. In malignant 
gliomas, HES6 plays important roles in cell proliferation and migration (8). HES6 
can antagonize Notch signaling by interacting with HES1 (9). Despite the fact that 
HES6 bears strong homology to known Notch pathway targets, whether Notch sig-
naling regulates HES6 is unknown. 
 Notch signaling is critical for cell-fate decisions in many organs (7), including the 
prostate. Adult prostate glands are composed of basal and luminal layers that have 
distinct androgen-responsiveness. Luminal cells express high androgen receptor (AR) 
levels and undergo apoptosis after androgen deprivation (10, 11). In contrast, basal 
cells do not rely on androgen to survive and are able to regenerate prostate glands af-
ter castration, once androgens are replenished (11). Studies of benign mouse prostate 
epithelium have revealed that Notch ligands and receptors are expressed in both bas-
al and luminal cells and can mediate physiologic proliferative responses that include 
response to androgen (12, 13). Prostate cancer cells almost universally emerge as 
androgen-dependent cells with a luminal cell phenotype. Upon androgen-deprivation, 
growth pauses until cells adapt to androgen-independent growth. Prostate cancer cell 
lines have been isolated from patients at different stages in this process, and can be 
classified as androgen-responsive or androgen-unresponsive. 
 In comparison to indolent cancers, aggressive prostate cancer cells upregulate not 
only HES6 but also the Notch ligand Jagged2, and the Notch3 receptor (5,6). Induc-
tion of a Notch ligand, a receptor, and a potential response gene, could represent an 
active signaling cascade in aggressive prostate cancers. If this is the case, then mea-
suring and targeting Notch signaling could be helpful in the diagnosis and treatment 
of aggressive prostate cancers. If HES6 is not a Notch target, then other pathways 
that regulate this gene might be useful for the same purposes. Here, we investigate 
expression and function of Notch signaling and HES6 in benign prostate and prostate 
cancer cells. 
Materials and Methods
Plasmids, virus and construct generation HES6 (clone LIFESEQ7399489, Open 
Biosystems)  was subcloned into the lentiviral vector pNL-EGFP/CMV-WPREdU3 to 
establish overexpressing stable cell lines. shRNAs targeting HES6 mRNAs were 
obtained from the Expression Arrest-TRC shRNA Libraries (TRCN0000017828). 
Notch3 intracellular domain construct (gift from Dr Nicolas Gaiano) was subcloned 
into pcDNA 3.1(-) (Invitrogen). The vectors used in dual-luciferase reporter assay 
experiments were CBFRE-luc (Addgene #26897) and pGL2 (Promega). 
Cell lines and cell culture Human cancer cell lines were obtained from the Amer-
ican Type Culture Collection and maintained in RPMI 1640 (Gibco) supplemented 
with 10% fetal bovine serum (FBS) and Penicillin-Streptomycin (Invitrogen), except 
VCaP and LnCaP96. VCaP were provided by Dr William B. Isaacs (Brady Urologi-
cal Institute, The Johns Hopkins University School of Medicine) and maintained in 
DMEM/10% FBS (Gibco) and LnCaP96 cells were a gift from Dr Alan K. Meeker 
(Brady Urological Institute, The Johns Hopkins University School of Medicine) gen-
erated by long-term culture of LnCaP in charcoal-stripped FBS. Prostate epithelial 
cells RWPE–1 and PrEC were cultured according to vendor’s instructions. All cell 
line identities were confirmed by forensic identity analyses within 6 months of use. 
For the androgen withdrawn experiments, LnCaP cells were washed with charcoal-
stripped FBS three times for 1h and incubated in 10% charcoal-stripped FBS con-
taining medium for 48h before stimulation with 10nM of dihydrotestosterone (DHT). 
Real-time PCR analysis Total RNA was isolated with RNeasy Mini kit (Qiagen) 
and cDNA was synthesized with 1 mg of total RNA using High-Capacity cDNA Re-
verse Transcription kit (Applied Biosystems). cDNA was amplified on a StepOne 
Plus (Applied Biosystems) using TaqMan gene-specific oligonucleotide primers or 
custom designed primers (Supplementary Table S1). To determine the genes differ-
entially expressed in cancer and benign cell lines, we designed Taqman gene plates 
comprising all Notch pathway members described in mammals and five housekeep-
ing genes. Results are presented as a heatmap using Euclidean distance and ward 
linkage for clustering using median centered delta CT values for each gene. 
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Immunoblotting Protein lysates in NuPAGE buffer (Invitrogen) were separated by 
gradient 4–12% BisTris Gel and transferred to polyvinylidene difluoride membrane. 
Primary antibodies used were rabbit monoclonal anti-Notch1 (D1E11; 1:1000; Cell 
Signaling), rabbit polyclonal anti-cleaved Notch1 (Val1744; 1:1000; Cell Signaling), 
rabbit monoclonal anti-Notch2 (8A1; 1:1000; Cell Signaling), rabbit polyclonal anti-
Notch3 (Pro2311; 1:1000; Cell Signaling), rabbit polyclonal anti-HES1 (ab71559; 
1:1000; Abcam), rabbit polyclonal anti-HEY1 (ab22614; 1:500; Abcam), rabbit 
polyclonal anti-HES6 (ab66461; 1:1000; Abcam), mouse monoclonal anti-glycer-
aldehyde–3–phosphate dehydrogenase (GAPDH) (clone 6C5; 1:1000; Santa Cruz 
Biotechnology). The membrane was incubated sequentially with primary antibodies 
(overnight at 4oC), horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-
mouse and chemiluminescent substrate (Thermo Fisher) before exposure to film. 
Luciferase reporter assay Cells were plated in 24–well plates and 24 hours 
later transfected using Lipofectamine2000 (Invitrogen) with pGL2 (control) or with 
CBFRE-luc to determine endogenous Notch pathway activity in prostate cells. After 
48 hours, luciferase activity was determined using Dual-Luciferase Reporter Assay 
system (Promega) and normalized to PrEC basal luminescence. All experiments 
were performed in triplicate. 
siRNA transient knockdown Notch3 siRNA (Supplementary Table 2) transient 
transfections (final concentration of 10 nmol/L) were carried out by using Lipo-
fectamine 2000 (Invitrogen), following the manufacturer's instructions. Nontargeting 
siRNA was used as a control. Cells were lysated for western blot 24 hours after 
siRNA transfection. 
DAPT treatment and IC50 assay 24 hours after seeding the cells, gamma secre-
tase inhibitor N-[N-(3,5–Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
(DAPT) was added to 200 ml of growth media per well in final concentrations rang-
ing from 1 nmol/L to 400 mmol/L. Viability was assayed (see below) after 96 hours. 
The half maximum inhibitory concentration (IC50) of DAPT was calculated using 
GraphPad Prism software.
Cell viability and proliferation assays 22Rv1 and LnCaP with stable shRNA 
HES6 knockdown or PC3 stably overexpressing HES6 were seeded (500 cells per 
well) in 96–well black flat-bottom tissue culture plates. Cell viability and growth was 
determined using Alamar Blue vital dye (Invitrogen) according to the manufacturer’s 
instructions. Values were reported as mean standard error of optical density of trip-
licate wells fro each concentration and time point. 
Immunohistochemistry and Immunofluorescence IHC and IF staining were 
performed as described previously (14, 15) using anti-Hes6 antibody (ab66461; 
1:1000; Abcam). Mann-Whitney test used for statistical analysis of HES6 staining 
intensity was measured automatic quantitative analysis. 
Androgen-deprived tissue in tissue microarray (TMA) We used a previously 
described TMA comprising formalin-fixed paraffin-embedded prostate cancer tissue 
from (n=55) patients treated with androgen-deprivation therapy prior to prostatec-
tomy and from (n=12) untreated controls (14). 
Invasion assays 22Rv1 or LnCaP cells infected with control or shHES6 lenti-
viruses (see plasmids and viruses above) were seeded at 7.5 x 104 cells/well or 
5 x 104 PC3 cells infected with control or HES6 overexpression lentiviruses. The 
assay was performed in triplicate and in two independent experiments as previously 
described (16). Student t test was used to evaluate significant differences and a 
statistical significance was considered at p < 0.05.
Colony-forming efficiency assay Colony-forming efficiency assays were con-
ducted as described earlier (17). All visible were counted and results presented as 
total number colonies stander error in two individual experiments. 
Gene expression arrays and data analysis Differential gene expression analysis 
was performed as previously described (6, 18, 19), using statistical packages from 
the R/Bioconductor project (20, 21). Briefly, gene expression was measured on the Il-
lumina HT–12 v4 whole genome gene expression microarray. For each individual mi-
croarray feature a generalized linear model was fit to estimate expression differences 
between groups. Moderated t-statistics were obtained by empirical Bayesian shrink-
age of log2 fold-change standard errors (22), and adjustment for multiple testing was 
obtained using the Benjamini and Hochberg method (23). Gene annotation for the 
microarray used in this study was obtained from the corresponding R-Bioconductor 
metadata packages.
Results
Notch pathway components in prostate carcinogenesis
 We investigated the expression of the 36 known and presumed Notch pathway 
components in a panel of commonly used prostate cell lines. Of the two benign pros-
tate lines studied, RWPE–1 and PrEC have been reported to show relatively luminal 
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and basal epithelial phenotypes (24, 25). The 5 cancer cell lines studied included 
two androgen unresponsive lines (DU145 and PC3), and three that are androgen 
responsive (22Rv1, LnCaP, and VCaP) (26, 27). Quantitative TaqMan PCR (qPCR) 
assays on cDNA prepared from prostate cell lines revealed Notch gene expression 
patterns that organized the cell lines clearly into distinct benign and cancer clusters 
(Fig. 1A). HES6 was most differentially expressed gene between benign cells and 
cancer cells with 4–fold higher transcript levels in cancer (Fig. 1B). Although not as 
dramatically, other targets, such as HEY1, HEY2 and HES4 also exhibited increased 
expression levels in cancer cells (Fig. 1B). In contrast, many canonical Notch sig-
naling components were downregulated in cancer cells, including DLL1 and JAG1 
ligands, NOTCH1, 2, and 4 receptors, and the target gene, HES2 (Fig. 1B).
Figure 1 — Notch pathway members’ expression in prostate cells 
A Heatmap with gene expression results of Notch pathway members across commonly used prostate cells. 
Color bars at the top of the heatmap represent groups of cells with similar phenotypes: blue — benign cells; 
yellow — androgen-independent cancer cell lines; green — androgen-responsive cancer cell lines. Hierarchi-
cal clustering of gene expression patterns clearly distinguishes benign from cancer cells. Genes circled in 
yellow are, along with HES6 and NOTCH3 that are relevant for our analysis, the most studied members of 
Notch pathway.
B qRT-PCR analysis of relative expression of Notch pathway members in cancer relative to benign cell lines. 
A log2 fold increase in the y axis represents an enrichment of the genes in cancer cells and negative values cor-
respond to genes downregulated in cancer cells. HES6 was most differentially expressed gene in cancer cells. 
In contrast, canonical Notch signaling components, including DLL1 and JAG1 ligands, NOTCH1 and NOTCH2 
receptors, were downregulated in cancer cells.
Notch signaling components in prostate cancer cell lines
 Since Notch3 levels were previously shown to be lowest in indolent prostate 
cancers and highest in aggressive, high Gleason grade tumors, we performed a 
subanalysis to further investigate receptor expression in cancer. Interestingly, the 
benign RWPE–1 cell line showed the highest levels of Notch3 expression, whereas 
benign PrEC cells showed the lowest Notch3 levels (Fig. 2A and Supplementary 
Fig. S1), contributing to an overall lower expression of Notch3 in cancer. The exclu-
sion of RWPE would make Notch3 the second most overexpressed gene in can-
cer, after HES6 (Supplementary Fig. S2). Of further interest, those cell lines with 
high Notch3 expression also showed increased HES6, and both of these genes 
were particularly elevated in three of four androgen-responsive prostate cell lines 
(RWPE–1, 22Rv1 and LnCaP but not VCaP) compared to androgen-independent 
lines (DU–145, PC3) (Fig. 2A). These results prompted us to explore whether or not 
Notch3 and androgens regulate HES6.
Notch signaling dynamics in prostate cancer
 Few previous studies have presented Notch signaling dynamics in prostate cells. 
We genetically and pharmacologically manipulated benign prostate cells and pros-
tate cancer cells, and used a variety of assays to measure effects on Notch pathway 
activity and cell viability.  At baseline, benign prostate cells showed significantly high-
er levels of Notch1 and Notch2 receptor protein than did prostate cancer cells (Fig. 
2B). To explore Notch activity levels, we introduced a Notch dependent luciferase 
reporter (28) into the 7 benign and malignant prostate lines profiled in this study. The 
benign cell lines RWPE–1 and PrEC showed the highest levels of RBPJ promoter 
basal activity, consistent with their overall higher expression of Notch receptors (Fig. 
2C). These results demonstrate lower levels of Notch signaling in prostate cancer 
cells compared to their benign counterparts and suggest a neutral or anti-oncogenic 
role for Notch in prostate epithelia.
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Figure 2 — Dynamics of Notch signaling in prostate cells
A Cell lines with high NOTCH3 expression also presented increased HES6. Immunoblot showing basal 
NOTCH3 and HES6 expression are globally higher in cancer cells confirming the expression pattern pre-
sented in the heatmap (Fig. 1A). 
B Benign cells have significantly higher levels of Notch receptor protein than cancer cells. Immunoblot show-
ing basal Notch1, Notch2, and Notch3. FL, full length NOTCH1; TM, transmembrane NOTCH1.
C Notch dependent luciferase reporter showed higher activity levels of RBPJ in benign cell lines. In benign 
cells a higher RBPJ promoter activity is consistent with overall high expression of Notch receptors. RLUs, Rela-
tive Luminescence Units.
Contributions of Notch3 receptor to Notch signaling and HES6 expression
 Different Notch receptor species can have different effects (29). Having established 
through its expression pattern that Notch3 was the receptor most correlated with 
HES6 expression in prostate cancer (Fig. 2A), we introduced constitutively active 
Notch3 intracellular domain (NICD3) into benign (RWPE–1 and PrEC) and cancer 
(22Rv1 and LnCaP) cells (Supplementary Fig. S3). Interestingly, qPCR analysis 
demonstrated that NICD3 overexpression in benign cell lines did not induce HES or 
HEY family members (Fig. 3A and data not shown), indicating that Notch signaling 
was unresponsive to NICD3 in these cells. Whereas most cancer cell lines also 
showed only modest responses to NICD3, 22RV1 cells responded with a 50% in-
duction of HES1 and five-times induction of HEY1 and HES5. Most notably, HES6 
was not induced by NICD3 in any of the cell lines we tested. These results indicate 
that some prostate cancer cell lines respond to Notch signaling, but that HES6 in-
duction is not part of that response.
Figure 3 — HES6 stands apart from the canonical Notch signaling pathway
A and B qPCR analysis of HEY1, HES1, HES5, and HES6 levels after NICD3 expression in benign and 
androgen-responsive cancer cell lines. Notch signaling was responsive to NICD3 only in 22Rv1 cancer cells.
C Immunoblot for HEY1 and HES1 validate the qPCR findings that NICD3 expression in 22Rv1 increases 
HEY1 protein levels.
D Immunoblot shows that the levels of HES6 remain unchanged after NOTCH3 knockdown in cancer cell lines.
 To confirm that HES6 is not under Notch3 control, we used siRNAs to knockdown 
Notch3 in the cancer cells with highest Notch3 and HES6 levels, 22Rv1 and LnCaP 
and determined the protein levels of HES6 and of HES1, a known Notch3 target (30). 
Upon effective Notch3 knockdown (Fig. 3D), HES1 levels correlated with levels of 
Notch1 protein (Fig. 2B): expression of this Notch target was maintained in 22RV1 
cells, but not in LnCaP cells (Fig. 3D). These data indicate that HES1 is a Notch tar-
get in prostate cancer cells and suggest that its expression in 22RV1 is redundantly 
supported by Notch1 and Notch3 but only by Notch1 in LnCaP cells. HES6 expres-
sion, in contrast, was unaffected by Notch3 knockdown (Fig. 3D). Thus, HES6 ex-
pression appears to be independent of Notch signaling. Neither engineered expres-
sion of NICD3 (Fig. 3B and 3C) nor Notch3 knockdown by siRNA (Fig. 3D) affected 
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HES6 levels. Although HES6 may interact with Notch signaling components, these 
results suggest that HES6 stands apart from the canonical Notch signaling pathway.
Prostate cancer cells are resistant to γ-secretase inhibition
 By pharmacologically inhibiting γ-secretase, and monitoring cleavage of Notch1 
protein into its active moiety, NICD1, we tested the effects of Notch pathway in-
hibition on cell growth and viability. The two benign cell lines PrEC and RWPE–1 
showed high levels of NICD1, but among 5 different cancer lines only one — 22Rv1 
— had detectable NICD1 levels (Fig. 4A). Treatment of these cells with increasing 
concentrations of γ-secretase inhibitor DAPT showed that 1 to 3 μM of DAPT were 
sufficient to block γ-secretase activity and eliminate NICD1 protein levels (Fig. 4B 
and 4C). Nevertheless, cell viability responses both in benign and cancer cells to 
DAPT required drug concentrations that were 30 to 40 times higher, most likely 
corresponding to off-target effects (Fig. 4D and Table 1). These results cast further 
doubt on the notion that Notch signaling is required for prostate cancer cell survival 
or growth.
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Figure 4 — Prostate cancer cells are resistant to γ-secretase inhibition
A Immunoblot shows γ-secretase cleaved NICD1 in the two benign cell lines PrEC and RWPE-1, and 22Rv1 
cancer cell line. 
B and C γ-secretase is inhibited in both benign and 22Rv1 cancer cells with 1 to 3 uM of DAPT. Immunoblot 
shows the levels of NICD1 protein after 48 hours treatment to the indicated concentrations of DAPT. 
D and E Prostate cells are resistant to γ-secretase inhibitor DAPT. Effects of DAPT on benign and tumor cells 
proliferation following incubation with increasing concentrations of DAPT. Error bars, mean ± SEM of triplicates. 
The table shows all cell lines were insensitive to DAPT with IC50 above 40μM, much higher concentrations than 
the ones required to inhibit γ-secretase.
Androgens downregulate Notch receptors while upregulating HES/HEY
family members
 Since there was a clear difference between two out of three androgen-responsive 
cell lines (22Rv1 and LnCaP) and androgen insensitive cell lines in Notch compo-
nent expression (Fig. 1A), we investigated how androgens affect the expression of 
different Notch pathway members in prostate cancer. For these studies, we utilized 
cell culture experiments and primary cancer tissue from human patients treated 
with androgen deprivation. We stimulated LnCaP with DHT and collected RNA 
for qPCR at time points up to 72 hours. Monitoring levels of transcripts encoding 
PSA, an androgen responsive gene (31), indicated effective androgen responses 
(Supplementary Fig. S4). Interestingly, we found that DHT modulated receptors 
and targets in opposite directions. NOTCH4 was undetectably low, regardless of 
androgen treatment. The expression of Notch receptors NOTCH1, NOTCH2, and 
NOTCH3 decreased over time with DHT administration whereas levels of HES1, 
HES6 and HEY1 increased (Fig. 5A and 5B). HES1 and HEY1 were particularly 
increased in the first 12 hours of DHT treatment. The effect diminished at later time 
points. HES6 did not increase as quickly or dramatically as HES1 and HEY1, but the 
response was more durable (Fig. 5B). These results indicate that HES/HEY family 
members respond to androgen stimulation independently of canonical Notch signal-
ing. This response occurs in two phases — rapid and transient induction of Notch 
targets HEY1 and HES1, and slow, sustained induction of HES6.
 To further investigate the long-term effects of androgen withdrawal, we assayed 
HES/HEY family member expression in LnCaP96, an LnCaP subline adapted to an-
drogen independent growth (32). In LnCaP96, mRNA levels for the androgen-regu-
lated gene, PSA were undetectable, whereas PSA was highly expressed in parental 
LnCaP cells (Fig. 5C). Compared to LnCaP levels, NOTCH3 levels in LnCaP96 were 
unchanged, whereas HES6 expression was significantly reduced (Fig. 5D). In agree-
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ment with these in vitro results, we found a significant reduction in HES6 staining 
intensity in cancers from men who had undergone a long-term ADT, compared to 
androgen-naïve cancers (Fig. 5E and 5F). In light of the dependence of Notch recep-
tor expression by androgen, these results raise the possibility that androgens induce 
HES/HEY family members in a Notch receptor-independent manner.
Figure 5 — Androgens downregulate Notch receptors and upregulate HES/HEY family members
A and B Effects on LnCaP Notch receptors and HES/HEY family members expression after incubation with 10 
nM of DHT. Transcript levels of NOTCH1, NOTCH2, and NOTCH3 decreased overtime and HEY1, HES1 and 
HES6 dramatically increased. Error bars, mean ± SEM of of three technical triplicates. 
C and D In the long-term androgen deprived subline LnCaP96, PSA levels are undetectable, NOTCH3 re-
mains unchangeable and HES6 expression is significantly reduced. Error bars, mean ± SEM of of three techni-
cal triplicates. 
E and F Photomicrographs of HES6 immunohistochemistry in prostate cancer glands with and without previ-
ous androgen deprivation. There is a significant decrease in HES6 expression (F) after androgen deprivation 
(*p=0.028, Mann–Whitney test).
HES6 contributes to prostate cancer aggressiveness
 As shown by qPCR array, HES6 transcripts were approximately 4–fold enriched 
in cancer cells compared to benign. In previous work, immunohistochemical analy-
sis of HES6 protein in human clinical samples (33) confirmed that the protein was 
upregulated in cancer and further demonstrated that strong nuclear HES6 protein 
expression increased as a function of Gleason grade, a potent indicator of meta-
static potential in prostate cancer.
 The ability to metastasize has been correlated with in vitro cell behaviors, including 
clonogenic growth and invasion through various matrices (34, 35). We up- and down-
regulated HES6 expression and assayed the effects on standard growth in culture, 
clonogenic growth, cell migration and invasion.
Figure 6 — HES6 promotes cancer cells invasion and colony formation
A Following HES6 shRNA knockdown in 22RV1 and LnCaP (left and middle) and HES6 overexpression in 
PC3 (right), cells were plated for alamarBlue proliferation assays. Growth curves show HES6 does not change 
proliferation in the three cell lines.
B Representative images of invasive 22Rv1 and LnCaP cells after HES6 shRNA knockdown. 
C Quantification of 22Rv1 and LnCaP HES6 knockdown invaded cells. Error bars, mean ± SEM.
D Representative images of invasive PC3 cells overexpressing (left) and quantification of invaded cells (right). 
Error bars, mean ± SEM.
E Representative pictures (left) and quantification (right) of colony-forming efficiency of 22Rv1 cells with HES6 
knockdown. Error bars, mean ± SEM.
F Representative pictures (left) and quantification (right) of colony-forming efficiency of PC3 cells overex-
pressing HES6. Error bars, mean ± SEM.
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
H
E
S
6 
st
ai
ni
ng
 
In
te
ns
ity
 s
co
re
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
A
bs
or
ba
nc
e 
at
 5
40
nm
A
bs
or
ba
nc
e 
at
 5
40
nm
A
bs
or
ba
nc
e 
at
 5
40
nm
N
um
be
r 
of
 c
ol
on
ie
s
N
um
be
r 
of
 c
ol
on
ie
s
R
el
at
iv
e 
ex
pr
es
si
on
82 83
 Using lentiviral plasmid transfer, we reversed baseline levels of HES6 (Fig. 2A) 
by stably engineered its expression into PC3 cells and knocked it down in 22Rv1 
and LnCaP cells (Supplementary Fig. 5A and 5B). Whereas HES6 overexpres-
sion or knockdown did not have a noticeable effect on cell viability or growth rate 
(Fig. 5A), HES6 significantly affected cell invasion. HES6 knockdown in 22Rv1 and 
LnCaP significantly impaired cell invasion through a matrigel membrane and PC3 
cells overexpressing HES6 showed a significant increase in their ability to invade 
compared to controls (Fig. 6B–D). In line with these observations, HES6 affects the 
clonogenic potential of cancer cells. HES6 knockdown in 22Rv1 and LnCaP cell did 
not significantly decrease the number of colonies, but HES6 overexpression in PC3 
increased the capacity of the cells to form colonies 4 times (Fig. 6E and 6F). As pre-
viously suggested by studies that showed that HES6 distinguishes prostate cancers 
with and without the ability to metastasize (6), these results strongly suggest that 
HES6 confers biological properties to cancer cells that enable them to escape the 
prostate and generate metastatic clones. 
HES6 controls a number of pathways that contribute to cancer progression
 To determine the pathways activated by HES6 in benign cells and the mecha-
nisms involved in the invasion and clonogenic advantage observed in cancer cells, 
we engineered HES6 overexpression and knockdown and comprehensively profiled 
changes in gene expression. Despite previous indicators that HES6 can downregu-
late Notch signaling, we saw no evidence that any Notch target was significantly 
modulated by HES6 (Fig. 7A). In contrast, HES6 modulated expression of a number 
of other pathways. The pathways activated by HES6 were different among benign 
and malignant cells (Fig. 7A). In benign cells, HES6 induced overexpression of 
genes, such as IRF4, LCK and BMX that are involved in immunosurveillance and 
kinases that increase cell survival (Fig 7B).
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Figure 7 — HES6 controls different pathways in benign and cancer cell lines
A HES6 expression in RWPE–1 and PC3, and knockdown in 22Rv1 and LnCaP altered the expression of 63 
genes that are members of different pathways. 
B C D E qPCR analysis of differentially expressed transcripts after HES6 overexpression in RWPE–1 (B) and 
PC3 (C), or HES6 knockdown in 22Rv1 (D) and LnCaP (E). Error bars, mean ± SEM of three technical replicates.
 Two significantly highly expressed genes, P2RY14 and PAPPA, were implicated 
lung tumor growth (36, 37). HES6 overexpression in RWPE–1 significantly downregu-
lated ATRX and DDX51 genes that encode proteins involved in chromatin remodeling 
and telomere lengthening. Interestingly, we found downregulation of DLK2, a gene 
encoding a protein that inhibits Notch signaling and one that was previously impli-
cated in prostate tumorigenesis (38). Also downregulated was suppressor of fused 
(SUFU), considered a tumor suppressor gene through its inhibitory influence on the 
Hedgehog pathway (Fig. 7B). Repression of SUFU by HES6 could represent a new 
mechanism of inducing Hedgehog signaling in prostate cancer, which could partici-
pate in prostate cancer development, metastasis and androgen-independent growth 
(39, 40). In PC3 prostate cancer cells, HES6 increased most significantly genes in-
volved in cell structure, motility, and tumor cells invasion and metastasis (Fig. 7C). 
Significantly overexpressed genes included three members of S100 family, S100A8, 
S100A9, and S100A14, serglycin (SRGN), myosin light chain kinase (MYLK), and 
the integrin beta 2 (ITGB2). These genes were previously implicated in cancer pro-
gression of several tumors, including the prostate: S100 proteins are overexpressed 
in prostate cancer and present in circulating tumor cells (41, 42); SRGN promoted 
metastasis in nasopharyngeal carcinoma (43); MYLK was identified in a microarray 
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study as one of the most discriminative genes between normal and prostate can-
cer (44); and integrin beta 2, as well as other integrins, are essential for different 
types of cancer cells to interact with the extracellular matrix and trigger intracellular 
signals to support survival and migration (45). In LnCaP and 22Rv1 cells, HES6 
knockdown modulated a set of genes that only partially overlapped with those af-
fected in PC3 cells, but the most highly affected pathways in all cancer cell lines 
were strikingly similar. HES6 knockdown in these 2 cell lines significantly diminished 
expression of genes involved in migration and invasion, including metalloproteinase 
7 (MMP7) and ITGB2 (Fig. 7D and 7E). In LnCaP cells, HES6 knockdown signifi-
cantly increase the expression of the G-protein GNG11, which beyond inducing cell 
senescence (46), is downregulated in splenic marginal zone lymphoma (47). HES6 
downregulation in LnCaP significantly increased CD24 (Fig. 7E). This cell surface 
protein plays important roles in cell-cell and cell-extracellular matrix interactions and 
some studies showed that it is highly expressed high grade prostate cancers (48). 
However, progenitor cancer cells with the ability to initiate new tumors, compared 
with differentiated cells, possess lower CD24 expression (49). In this context, HES6 
may provide tumor-initiation properties to prostate cancer cells and the knockdown 
of HES6 lead to an increase of CD24 contributing to a less aggressive phenotype 
of cancer cells. 
Discussion
 Our results confirm differential expression of Notch pathway members in aggres-
sive prostate cancer and indicate a role for HES6 in tumor progression. These ef-
fects result from a direct action of HES6 or activation of other pathways. These data 
suggest that Notch signaling, and particularly HES6, may be useful in distinguishing 
indolent from lethal prostate cancers.
 In our studies, Notch receptor expression and Notch signaling activation is in-
versely correlated with malignant phenotype of cancer cells. We found that prostate 
benign cells have higher Notch1 and Notch2 expression and more Notch pathway 
activation than cancer cells. Notch pathway blockade, a proposed therapeutic mo-
dality for breast cancer (50) had no effect on prostate cancer viability. To the extent 
that in vitro assays reflect cancer biology in vivo, these results suggest that Notch 
blockade may not be therapeutically helpful in prostate cancer patients. 
 In contrast, HES6, although homologous to Notch pathway targets, is regulated 
independently from Notch and may be helpful in prostate cancer diagnostic and 
prognostic settings. HES6 interacts with Notch signaling components (9), but is not 
regulated by Notch receptors. HES6 modulates pathways involved in cancer colony 
formation, invasion and migration such as integrins, and these pathways are poten-
tial targets for prostate cancer therapy. We found a significant decrease in HES6 
expression in cell lines cultured in androgen-deprived media and in prostate cancer 
specimens from patients treated with ADT. However, in a variable time frame, prostate 
cancer becomes resistant to ADT and cancer cells are able to reactivate AR signaling. 
In this setting, it is possible that other genes possibly assume the role of HES6.
 Our results show that HES6 reflects and mediates the aggressive phenotype in 
hormone-naïve prostate cancers. The identification of the invasion and clonogenic 
advantages conferred by HES6 to cancer cells, and other cellular pathways it acti-
vates may open new avenues to interfere with prostate cancer progression.
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Supplementary Figure 1 — qRT-PCR analysis for NOTCH3 expression in prostate cell lines. Error bars, mean 
± SEM of three technical replicates.
Supplementary Figure 2 — qPCR analysis of Notch pathway members expression in cancer cell lines relative 
to PrEC. The exclusion of RWPE–1 from the analysis causes a significant increase in NOTCH3 in cancer cells.
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Supplementary Figure 3 — qPCR shows increase in NOTCH3 transcripts after overexpression of NICD3. We 
used TaqMan primers to detect increase in NICD3 transcripts because the antibody used to detect NOTCH3 
protein expression in western blots (Pro2311; Cell Signaling) recognizes the transmembrane domain and is unable 
to detect the intracellular portion of the receptor.
Supplementary Figure 4 — qPCR shows PSA transcript levels at several time points after DHT stimulation 
of LnCaP cells.
Supplementary Figure 5 — Manipulation of HES6 protein levels in cancer cell lines
A and B Photomicrographs of HES6 immunofluorescence in 22Rv1 (top panel) and LnCaP (lower panel) cells 
after HES6 knockdown, and PC3 (B) cells overexpressing HES6. Scale bar, 200μm.
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Supplementary Table S1 — 
Gene Name
Eukaryotic 18S rRNA
Actin, beta
Hypoxanthine phosphoribosyltransferase 1
Glucuronidase, beta
Jagged 1
Jagged 2
Numb homolog (Drosophila)-like
Delta-like 1 (Drosophila)
Mastermind-like 1 (Drosophila)
Anterior pharynx defective 1 homolog A (C. elegans)
Delta-like 3 (Drosophila)
F-box and WD repeat domain containing 7
Anterior pharynx defective 1 homolog B (C. elegans)
Presenilin 1
Presenilin 2 (Alzheimer disease 4)
SNW domain containing 1
Mastermind-like 3 (Drosophila)
Nicastrin
Notch 1
Notch 2
Notch 3
Notch 4
Mastermind-like 2 (Drosophila)
Presenilin enhacer 2 homolog (C. elegans)
Recombination signal binding protein
for immunoglobulin kappa J region
ADAM metallopeptidase domain 17
LFNG O-fucosylpeptide 3–beta-N-acetylglucosaminyltransferase
RFNG O-fucosylpeptide 3–beta-N-acetylglucosaminyltransferase
Delta-like 1 homolog (Drosophila)
Hairy and enhancer of slip 1 (Drosophila)
Hairy and enhancer of slip 2 (Drosophila)
Hairy and enhancer of slip 3 (Drosophila)
Hairy and enhancer of slip 4 (Drosophila)
Hairy and enhancer of slip 5 (Drosophila)
Hairy and enhancer of slip 6 (Drosophila)
Hairy and enhancer of slip 7 (Drosophila)
Hairy/enhancer of slip related with YRPW motif 1
Hairy/enhancer of slip related with YRPW motif 2
Hairy/enhancer of slip related with YRPW motif-like
Numb homolog (Drosophila)
Ribosomal protein 18
Gene Symbol
18S
ACTB
HPRT 1
GUSB
JAG 1
JAG 2
NUMBL
DLL 1
MAML 1
APH1A
DLL 3
FBXW7
APH1B
PSEN1
PSEN2
SNW1
MAML3
NCSTN
NOTCH 1
NOTCH 2
NOTCH 3
NOTCH 4
MAML 2
PSENEN
RBPJ
ADAM 17
LFNG
RFNG
DLK 1
HES 1
HES 2
HES 3
HES 4
HES 5
HES 6
HES 7
HEY 1
HEY 2
HEYL
NUMB
RPL 18
Assay ld
Hs99999901_s1
Hs99999903_m1
Hs99999909_m1
Hs99999908_m1
Hs00164982_m1
Hs00171432_m1
Hs00191080_m1
Hs00194509_m1
Hs00207373_m1
Hs00211268_m1
Hs00213561_m1
Hs00217794_m1
Hs00229911_m1
Hs00240518_m1
Hs00240982_m1
Hs00273351_m1
Hs00298519_s1
Hs00299716_m1
Hs01062011_m1
Hs01050719_m1
Hs01128541_m1
Hs00965889_m1
Hs00418423_m1
Hs00708570_s1
Hs00794653_m1
Hs01041915_m1
Hs01046129_m1
Hs01357010_g1
Hs00171584_m1
Hs00172878_m1
Hs00219505_m1
Hs01367669_g1
Hs00368353_g1
Hs01387464_g1
Hs00936587_g1
Hs00261517_m1
Hs00232618_m1
Hs00232622_m1
Hs00232718_m1
Hs00377772_m1
Hs00965812_g1
Supplementary Table S2 A — 
Gene Name
Prostate-spesific antigen
Hypoxanthine phosphoribosyltransferase 1
DNA (cytosine–5)-methyltransferase 3 beta
Purinergic receptor P2Y G-protein
coupled 14
Pregnancy-associated plasma protein A, 
pappalysin 1
Serglycin
Suppressor of fused homolog (Drosophila)
Interleukin 1 beta
BMX non-receptor tyrosine kinase
Alpha thalassemia/mental retardation 
syndrome X-linked
B-cell CLL/lymphoma 2
Baculoviral IAP repeat containing 3
DEAD (Asp-Glu-Ala-Asp) box polypeptide 51
Delta-like 2 homolog (Drosophila)
Interferon regulatory factor 4
Lymphocyte-specific protein tyrosine kinase
Myosin light chain kinase
Ras-related C3 botulinum toxin substrate 1 
(rho family, small GTP binding protein Rac1)
Integrin, beta 2 (complement component 3 
receptor 3 and 4 subunit)
WNK lysine deficient protein kinase 3
Aldehyde dehydrogenase 1 family, 
member A2
Basal cell adhesion molecule
(Lutheran blood group)
CD24 molecule
Forkhead box O3
Mitogen-activated protein kinase kinase 2
Matrix metallopeptidase 7
(matrilysin, uterine)
Methylthioadenosine phosphorylase
SRY (sex determining region Y)-box 6
STIP1 homology and U-box containing 
protein 1, E3 ubiquitin protein ligase
Sushi domain containing 1
TNF receptor-associated factor 4
Recombination signal binding protein for 
immunoglobulin kappa J region
Forward
TGAACCAGAGGAGTTCTTGAC
TGGGAGGCCATCACATTGTA
AGGGAAGACTCGATCCTCGTC
TACGTGCCCAGCTCTAAGAGT
ACAAAGACCCACGCTACTTTTT
GGACTACTCTGGATCAGGOTT
GCCTGAGTGATCTCTATGGTGA
ATGATGGCTTATTACAGTGGCAA
GAGTGCTGAAGATACCTCGGG
GCAACCTTGGTCGAAAGGAGT
GGTGGGGTCATGTGTGTGG
TTTCCGTGGCTCTTATTCAAACT
GGCTGGCTGAGCCTAACTG
GTACCATTGTGTGTGCTTACCA
GCTGATCGACCAGATCGACAG
TGCCATTATCCCATAGTCCCA
CCCGAGGTTGTCTGGTTCAAA
ATGTCCGTGCAAAGTGGTATC
AAGTGACGCTTTACCTGCGAC
ACTTCTCCTAGTGGCAGATTCC
TTGCAGGGCGTCATCAAAAC
CAGGTCACAATGCACGACAC
CTCCTACCCACGCAGATTTATTC
ACGGCTGACTGATATGGCAG
AGGTCCTGCACGAATGCAA
GAGTGAGCTACAGTGGGAACA
ACCACCGCCGTGAAGATTG
TACCTCTACCTCACCACATAAGC
AGCAGGGCAATCGTCTGTTC
GGGCAGCCAGGTTCGTTAT
CAGGAGAGTGTCTACTGTGAGA
AACAAATGGAACGCGATGGTT
Gene Symbol
PSA
HPRT
DNMT3B
P2RY14
PAPPA
SRGN
SUFU
IL1B
BMX
ATRX
BCL2
BIRC3
DDX51
DLK2
IRF4
LCK
MYLK
RAC1
ITGB2
WNK3
ALDH1A2
BCAM
CD24
FOXO3
MAP2K2
MMP7
MTAP
SOX6
STUB1
SUSD1
TRAF4
RBPJ
Reverse
TGACGTGATACCTTGAAGCA
CCAGCAGGTCAGCAAAGAATT
GTGTGTAGCTTAGCAGACTGG
GTCACCAAGGATCTTGAAAGGAA
CATGAACTGCCCATCATAGGTG
CAAGAGACCTAAGGTTGTCATGG
TCTCTCTTCAGACGAAAGGTCAA
GTCGGAGATTCGTAGCTGGA
CGTTGTCATATTGGGCTAGAGTG
GGCTCTGGGTGACAAATGTAG
CGGTTCAGGTACTCAGTCATCC
GCACAGTGGTAGGAACTTCTCAT
GGACTGGAAAGTAGGACGAGAT
CAGGCAGTCATCCACATTTACC
CGGTTGTAGTCCTGCTTGC
GAGCCTTCGTAGGTAACCAGT
GCAGGTGTACTTGGCATCGT
CTCGGATCGCTTCGTCAAACA
AAGCATGGAGTAGGAGAGGTC
GCAGCTCACACCAAGCAAC
ACACTCCAATGGGTTCATGTC
CACCACGCACACGTAGTCT
AGAGTGAGACCACGAAGAGAC
CGTGATGTTATCCAGCAGGTC
CGTCCATGTGTTCCATGCAA
CTATGACGCGGGAGTTTAACAT
GCATCAGATGGCTTGCCAA
ACATCGGCAAGACTCCCTTTG
CAAGGCCCGGTTGGTGTAATA
TCTGGAGGGTTGCCACAGT
CCACACCACATTGGTTGGG
GGCTGTGCAATACTTCTTTCCTT
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Gene Name
S100 calcium binding protein A14
S100 calcium binding protein A8
S100 calcium binding protein A9
STEAP family member 4
Acyl-CoA synthetase long-chain
family member 5
Annexin A2
Rho GDP dissociation inhibitor (GDI) beta
ATP synthase H+ transporting 
mithochondrial Fo complex subunit G
Bardet-Biedl syndrome 10
Breast carcinoma amplified sequence 2
Calbindin 2
Cyclin D2
Calcium and integrin binding
family member 3
Cornichon homolog 3 (Drosophila)
Deleted in malignant brain tumors 1
Eukaryotic translation initiation factor 4E
EPH receptor B2
Fasciulation and elongation protein zeta 1 
(zygin l)
Galactosidase alpha
GLI pathogenesis-related 1
Guanine nucleotide binding protein
(G protein), gamma 11
Interleukin 22
Keratin associated protein 3–1
Mitogen-activated protein kinase 11
MAX-like protein X
MutS homolog 2, colon cancer, 
nonpolyposis type 1 (E. coli)
Prostate and testis expressed 3
Piccolo (presynaptic cytomatrix protein)
Phosphoinositide–3–kinase, class 3
PC4 and SFRS 1 interacting protein 1
Resistin like beta
Short chain dehydrogenase/reductase 
family 9C, member 7
Sushi domain containing 5
Forward
GAGACGCTGACCCCTTCTG
ATGCCGTCTACAGGGATGAC
GGTCATAGAACACATCATGGAGG
CCTCAGCCCTTCAAATCTCAG
CTCAACCCGTCTTACCTCTTCT
GAGCGGGATGCTTTGAACATT
GACTGGGGTGAAAGTGGATAAAG
ATGGCCCAATTTGTCCGTAAC
CCGAGGGACGGCAAGTTTT
TGGATGCGCTGCCGTATTTT
AGCGCCGAGTTTATGGAGG
TTTGCCATGTACCCACCGTC
GCGTATCAGGACTGCACATTT
GAGCCCCATAGACCAGTGC
CAAGGACTACAGACTACGCTTCA
GAAACCACCCCTACTCCTAATCC
GTGTGCAACGTGTTTGAGTCA
CCACTGGTGAGTCTGGATGAA
TTGGATACTACGACATTGATGCC
TCCGATCAGAGGTGAAACCAA
CCTGCCCTTCACATCGAAGAT
GCTTGACAAGTCCAACTTCCA
ACCTGCCCACATGAGATCAG
AAGCACGAGAACGTCATCGG
TGTCCACGTTACGCAAGGATG
CACTGTCTGCGGTAATCAAGT
ATCACTTCAGTGCATAACATGCC
TGTTACCACTACATCAGCACTGA
GTCTGGCCTAATGTAGAAGCAG
CAACAGGCAGCAACTAAACAATC
CCGTCCTCTTGCCTCCTTC
CAGCGGGATACCTCCTATCG
GTGGTACAGGATTGCTCCTTTG
Gene Symbol
S100A14
S100A8
S100A9
STEAP4
ACSL5
ANXA2
ARHGDIB
ATP5L
BBS10
BCAS2
CALB2
CCND2
CIB3
CNIH3
DMBT1
EIF4E
EPHB2
FEZ1
GLA
GLIPR1
GNG11
IL22
KRTAP3–1
MAPK11
MLX
MSH2
PATE3
PCLO
PIK3C3
PSIP1
RETNLB
SDR9C7
SUSD5
Reverse
CTTGGCCGCTTCTCCAATCA
ACTGAGGACACTCGGTCTCTA
GGCCTGGCTTATGGTGGTG
ACATGGCATGATTAGGACAAACT
GCAGCAACTTGTTAGGTCATTG
TAGGCGAAGGCAATATCCTGT
TCGTCGGTGAAGAAGGACTTG
TGGCGTAGTACCAAAATGTGG
TGGGATGCTCTAAGTGTAGCG
GGTATCTGCGAGTTTCCTCCTC
TGGTTTGGGTGTATTCCTGGA
AGGGCATCACAAGTGAGCG
GCAGGTGGTATAGTCGAGGG
CACCAGCTTTCGCAGAAGGA
TCCGAGGGAAATGGAGAACCT
AGAGTGCCCATCTGTTCTGTA
ACGCACCGAAAACTTCATCTC
CGGAAGAAAAATTCTCAAGCTCG
TTCTGCCAGTCCTATTCAGGG
GGCTTCAGCCGTGTATTATGTG
CTTCTTTGCGAAGCTGCTCAA
GCTGACTCATACTGACTCCGT
GGCACATAGGTATCAGGCTTG
TCACCAAGTACACTTCGCTGA
GGTGTGCCTTCACAATCTGCT
CTCTGACTGCTGCAATATCCAAT
CTCGCCCTTCTGAGCAGTA
AGCCATGAAGGGTTGGTTGTT
GGCAAGACGGCTCATCTGAT
TCATGGTCGGTATCTTCCTTTGA
CTTTTGACACTAGCACACGAGA
GCCTTGTTCGCCCACTTTG
CCACTTCCTTTGCTACACACAG
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Abstract
Background Though active surveillance is increasingly recommended, approxi-
mately one third of patients with Gleason score 3+3=6 (GS6) cancer on biopsy are 
upgraded to higher GS at radical prostatectomy (RP). Clinical-pathologic param-
eters are only weak predictors of upgrading.
Objective To investigate whether PTEN loss in GS6 biopsies is associated with 
upgrading at RP.
Design, setting and participants 71 patients with GS6 tumors on needle biopsy 
upgraded to GS7 or higher cancer at RP (cases) were compared to 103 patients 
with GS6 on both biopsy and RP (controls). Patients were from tertiary care and 
community care settings.
Outcome Measurements and Statistical Analysis A previously validated im-
munohistochemical (IHC) assay for PTEN loss was performed on all biopsies, fol-
lowed by fluorescence in situ hybridization (FISH) to detect PTEN gene deletion in 
biopsies with PTEN loss. The association of PTEN loss with upgrading and clinical-
pathologic variables was assessed by logistic regression.
Results and limitations Upgraded patients were older than controls (61.8 vs. 
59.3 years), had higher pre-operative PSA levels (6.53 vs. 5.26 ng/mL), and had 
a higher fraction of involved cores (0.42 vs. 0.36). PTEN loss by IHC was found in 
18.3% (13/71) of upgraded cases compared to 6.8% (7/103) of controls (p=0.02). 
Of these biopsies with PTEN protein loss, FISH demonstrated homozygous PTEN 
deletion in 90% (9/10) of upgraded tumors compared to 67% (4/6) of controls. Tu-
mors with PTEN loss were significantly more likely to be upgraded at RP than those 
without loss, even after adjusting for age, preoperative PSA, clinical stage and race 
(OR = 3.04 [1.08–8.55; p=0.035]).
Conclusions PTEN loss in GS6 biopsies is associated with upgrading at RP.
Patient summary A simple test can be conducted on low grade prostate cancer 
biopsies to help identify patients with potentially unsampled higher risk disease who 
may not be good candidates for active surveillance.
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Introduction
 Based on pathologic examination of the entire prostate, the Gleason grading 
system distinguishes between indolent Gleason score 3+3=6 (GS6) cancers and 
cancers with lethal potential, virtually all of which are Gleason score 3+4=7 (GS7) or 
higher [1–5]. If this information were available at the time of diagnosis, it would be 
relatively simple to identify appropriate candidates for deferred treatment or active 
surveillance (AS) in place of definitive therapy. However, a recent meta-analysis, 
including more than 14,000 cases, suggests that this is frequently not the case: a 
mean of 36% (range: 14–51%) of apparently indolent GS6 tumors on needle biopsy 
are “upgraded” to GS7 or higher at RP [6].
 Currently, there are relatively few predictors of which patients with GS6 prostate 
tumors on needle biopsy are likely to harbor higher grade disease. Tumor upgrading 
from needle biopsy to RP can occur for multiple reasons, including tumor progres-
sion, pathology errors, and inter-observer variability in Gleason grading. However, a 
common cause is under-sampling of the highest Gleason score cancer [6]. Unfortu-
nately, increasing the number of needle cores above the current standard of 12 does 
not substantially reduce the frequency of upgrading [7]. While MRI-based imaging 
is becoming more promising in this regard [8], imaging is expensive and not widely 
used. Further, prior studies have found that clinical-pathologic parameters such as 
higher preoperative PSA, lower prostate volume, and more extensive disease on 
biopsy are relatively weak predictors of upgrading [9–15]. To date, no molecular 
biomarkers have been validated for association with upgrading.
 We and others have shown that PTEN, a tumor suppressor, is most commonly 
lost in prostate tumors with high Gleason grade and high stage [16–25]. Recently, 
we developed and validated a simple and inexpensive immunohistochemical (IHC) 
assay to assess PTEN status in prostate cancer [16]. Using this assay, we showed 
that PTEN protein loss, assessed by a simple dichotomous scoring system, is 
highly correlated with underlying genetic deletions of the PTEN gene and is as-
sociated with decreased time to biochemical recurrence, disease progression and 
metastasis in contemporary surgical cohorts [16–18]. Here, we demonstrate that 
PTEN loss in GS6 needle biopsy specimens is associated with GS upgrading in 
the final RP specimen.
Patients and Methods
Patients and tissue samples With institutional review board approval, the Johns 
Hopkins Hospital (JHH) Pathology database was queried for all needle biopsies per-
formed at JHH (a tertiary care hospital) or Johns Hopkins Bayview Medical Center 
(BMC, a community care setting) that contained only GS6 tumor followed by a radical 
prostatectomy (RP) specimen that contained GS7 or higher tumor occurring between 
2000–2011. Controls with GS6 tumor on biopsy followed by GS6 tumor on RP were 
selected from sequential biopsies occurring between 2000–2004 at JHH and 2000–
2011 at BMC. As is routine at JHH and BMC, all RP specimens were entirely submit-
ted and processed for histologic analysis. All biopsies and RP slides were re-reviewed 
and re-graded by trained uropathologists (DMB and TLL) using the 2005 modified 
International Society of Urologic Pathology (ISUP) grading system [26]. Each case 
was assigned a primary, secondary and tertiary (for RP specimens) Gleason pattern. 
Upgrading was defined by the Gleason score without reference to the tertiary compo-
nent since studies from the era predating the use of tertiary grades support the neg-
ligible lethality associated with GS6 tumors [1]. A single block (generally consisting of 
two cores) containing the largest percentage involvement by tumor was selected for 
PTEN immunostaining described below.
PTEN Immunohistochemistry and interpretation PTEN IHC was performed as 
previously described and blindly scored by two uropathologists (TLL and DMB) us-
ing a previously validated dichotomous scoring system [16]. In cases where the two 
scoring uropathologists disagreed (17/174 or 10% of total), a third uropathologist 
(AMD) blindly scored the case to break the tie.
PTEN FISH Four-color FISH was performed and interpreted as described previ-
ously using the PTEN del-TECT probe (CymoGen Dx, LLC, New Windsor, NY) [23, 
www.ptendeletion.net]. A hematoxylin and eosin stained needle core section was 
available for comparison to confirm marked regions of interest. 
Statistical analysis Means and proportions of pre-and post-operative character-
istics of cases and controls were compared using the two-sample t-test and the chi-
square test, respectively. Multivariable logistic regression was used to estimate the 
odds ratios (ORs) and 95% confidence intervals (CI) of a biopsy upgrade among 
men with PTEN loss. First, ORs were estimated adjusted for age at diagnosis. Next, 
results were adjusted for preoperative PSA (continuous, log-transformed) and clinical 
stage (binary, T2 or higher). Results were further adjusted for race (binary, nonwhite). 
Statistical analyses were performed using SAS 9.3 (Cary, NC).
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Results
Pre-operative clinical-pathologic parameters The mean age of the 71 upgrad-
ed cases was slightly older than that of the 103 controls who were not upgraded 
(61.8 vs. 59.3 years; p=0.005) (Table 1). The racial makeup of the two cases and 
controls was not significantly different. The mean pre-operative serum PSA level 
was 23% higher in the upgraded cases (6.53 vs. 5.26 ng/mL; p= 0.009), but there 
was no difference in clinical stage distribution between the two groups. The majority 
of patients underwent RP within 3 months of biopsy diagnosis and there was no 
significant difference in the pre-operative interval between groups.
Variable
Age at diagnosis [mean (SD)]
Non-white (%)
Pre-operative PSA (ng/mL) [mean (SD)]
PSA density* [mean (SD)]
Clinical Stage (%)
1 – T1c
2 – T2a
3 – T2b
% missing
Days between biopsy and RP [mean (SD)]
Number of cores sampled [mean (SD)]
Less than 12 cores sampled (%)
Number involved cores [mean (SD)]
Fraction involved cores [mean (SD)]
Maximum percent tumor per core [mean (SD)]
Bilateral involved cores (%)
Perineural invasion (%)
PTEN loss by IHC (%)
Controls
59.3 (6.2)
21.4
5.26 (2.95)
0.10 (0.07)
83.7
13.3
3.0
4.9
90.6 (53)
12.2 (1.1)
3.9
3.6 (2.2)
0.3 (0.18)
48 (25)
41.2
22.3
6.8
Cases
61.8 (5.3)
29.6
6.53 (3.40)
0.13 (0.08)
89.4
9.1
1.5
7.0
103.7 (54)
11.9 (1.1)
8.5
4.2 (2.3)
0.36 (0.21)
51 (27)
54.9
25.4
18.3
P
0.005
0.22
0.009
0.002
0.57
0.12
0.06
0.20
0.08
0.04
0.40
0.07
0.64
0.02
*PSA density was calculated using the prostate weight at radical prostatectomy.
Table 1 — Pre-Operative Characteristics of Cases and Controls (103 Controls, 71 Cases)
Variable
Gland weight [mean (SD)]
Pathologic stage (%)
T2
T3a
T3b
Node positive
% missing
Path stage > T2 (%)
% missing
Positive margins
PSA recurrence (%)
% missing
Years of followup [mean (SD)]
Controls
59.8 (28.9)
82.3
15.7
2.0
0.0
1.0
17.6
1.0
7.8
1.2
19.4
4.5 (3.4)
Cases
54.4 (23.0)
65.2
27.5
7.3
1.5
2.8
34.8
2.8
23.9
8.8
19.7
3.6 (3.2)
P
0.17
0.03
0.23
0.0107
0.003
0.10
 Greater than 90% of both cases and controls had a 12–core biopsy performed, 
with a comparable number of cores examined in the cases compared to the controls 
(12.2 vs.11.9; p=0.06). The fraction of cores involved by tumor was slightly higher in 
the cases (0.36 vs. 0.30; p=0.04), however the maximum percent tumor per core was 
not significantly different between groups. Tumor was present on bilateral cores (from 
the left and right prostate) in a higher percentage of the upgraded cases compared 
to controls (54.9% vs. 41.2%, p=0.07). Finally, the fraction of cases with perineural 
invasion was not significantly different between groups.
 Post-operative clinical-pathologic parameters: To validate the clinical significance 
of tumor upgrading, post-operative clinical-pathologic parameters for the two groups 
of patients were assessed (Table 2). Upgraded cases had smaller mean prostate 
weights at RP (54.4 vs. 59.8 grams) although this did not reach statistical significance 
(p=0.17). As expected, upgraded cases were significantly more likely to have had 
extraprostatic extension or seminal vesicle involvement at RP than controls (34.8% 
vs. 17.6%; p = 0.01). Accordingly, upgraded cases were more likely to have positive 
margins at RP (23.9% vs. 7.8%; p=0.003) as well as PSA recurrence (8.8% vs. 1.2%; 
p=0.03), with a mean follow-up period of 3.6 and 4.5 years respectively for the roughly 
80% of patients with available information in each group.
Table 2 — Post-operative Characteristics of Cases and Controls (103 Controls, 71 Cases)
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PTEN protein loss and PTEN gene status PTEN protein loss was present in 
18.3% (13/71) of the upgraded tumors compared to only 6.8% (7/103) of the con-
trols (p=0.02). A subgroup analysis of the two hospital populations included in the 
study showed nearly identical results in both patient populations (17.9% and 20% 
for cases in JHH and BMC respectively; and 6.9% and 6.4% for controls, respec-
tively). PTEN protein loss was frequently focal within a given tumor sample (Figures 
1 and 2) with heterogeneous PTEN staining in 85% (11/13) of the upgraded cases 
with PTEN loss and 100% (7/7) of the controls.
Figure 1 — Gleason Score 6 prostate biopsies that are upgraded to Gleason Score 7 at radical prostatectomy 
show PTEN protein loss by immunohistochemistry (IHC)
A Low power (200x magnification) photomicrograph of PTEN IHC in a GS6 needle biopsy specimen demon-
strates PTEN protein loss in tumor glands (arrow) with preservation of PTEN staining in intermingled benign 
glands (arrowheads)
B High power (630x) image highlights infiltrating tumor glands with PTEN loss and surrounding benign glands 
with intact staining
C Low power (200x magnification) photomicrograph of tumor with heterogeneous PTEN loss, demonstrating 
PTEN loss in some tumor glands (arrow) and intact PTEN protein in adjacent tumor (arrowhead)
D High power (630x) image showing tumor glands with and without PTEN protein loss. Note the presence of 
apical membrane staining and rare nuclear PTEN in glands with cytoplasmic PTEN loss, though the significance 
of these findings is unclear.
 A recently developed 4–color FISH assay [23] was used to assess for PTEN 
gene deletions in the 20 biopsies with decreased PTEN protein by IHC. PTEN 
FISH was evaluable in 86% of the non-upgraded controls (6/7) and 77% (10/13) 
of the upgraded cases. Biopsies that could not be evaluated included those where 
the FISH hybridization failed (n=2) or where the tumor area with decreased PTEN 
protein could not be aligned on the adjacent histologic section on which the FISH 
was performed (n=2). Among the evaluable upgraded cases, 90% (9/10) of the 
biopsies with decreased PTEN protein showed homozygous PTEN deletions by 
FISH, variably involving the adjacent gene probes for FAS and WAPAL (Figure 2).
 Only one upgraded case (10%) with PTEN protein loss lacked PTEN gene 
deletion as assessed by FISH. Among the evaluable non-upgraded controls that 
showed unambiguous loss of PTEN protein by IHC, 67% had homozygous PTEN 
gene deletions (4/6), while 17% (1/6) had a hemizygous deletion and 17% (1/6) 
had no apparent PTEN deletion. In cases where PTEN protein loss was focal by 
IHC, PTEN FISH was evaluated in both the tumor areas with and without PTEN 
protein immunostaining. In these heterogeneous cases, the FISH for PTEN gene 
deletions was generally concordant with the IHC (Figure 2). Thus, FISH analysis 
confirmed the results of IHC analysis in 87% of evaluable cases.
 Association of PTEN protein loss and upgrading: Logistic regression was per-
formed to assess whether PTEN loss was independently associated with GS 
upgrading (Table 3).
 The variables adjusted in the multivariable analysis were those that have been 
found to be associated with upgrading in the current and multiple prior studies, 
including patient age and race, pre-operative PSA level and clinical stage. Even 
after adjusting for all of these variables (Model B), the odds ratio of GS upgrading 
was 3.04 (95% confidence interval: 1.08-8.55; p= 0.035) for PTEN protein loss.
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Figure 2 — PTEN FISH results are highly concordant with PTEN immunohistochemistry (IHC)
A PTEN IHC image (200x magnification) demonstrating PTEN protein loss in tumor glands (arrow) and PTEN 
protein retention in nearby benign glands (arrowhead)
B PTEN FISH image captured from the tumor in (A) demonstrates glands with homozygous PTEN loss (orange 
signal; arrow and upper right panel) intermixed with glands with PTEN intact (orange signal; arrowhead, lower 
right panel). Peri-centromeric control probes (red) as well as flanking gene probes WAPAL (green) and FAS 
(aqua) are intact in all cells
C PTEN IHC image (200x magnification) from a separate Gleason score 6 biopsy that was not upgraded at 
radical prostatectomy demonstrating focal loss of cytoplasmic PTEN protein in tumor glands (arrow). Adjacent 
tumor glands stain positively
D PTEN FISH image captured from tumor in (C) demonstrates diploid tumor cells throughout (inset)
E PTEN IHC image (100x) demonstrates PTEN protein loss in tumor glands (red outline) with PTEN protein 
retention in adjacent benign glands (blue outline)
F Higher power (630x) image of boxed area from (E)
G PTEN FISH image captured from region delineated in (E) demonstrates intermixed glands with hemizygous 
PTEN, WAPAL and FAS deletion (arrow, inset) and diploid glands (arrowhead)
Model
Age-adjusted
Multivariable-adjusted A*
Multivariable-adjusted B†
OR (95% CI)
2.93 (1.08-7.95)
2.81 (1.01-7.82)
3.04 (1.08-8.55)
P
0.034
0.047
0.035
* Additionally adjusted for preoperative PSA (continuous, log-transformed), and clinical stage (binary, T2 or higher)
† Additionally adjusted for preoperative PSA (continuous, log-transformed), clinical stage (binary, T2 or higher), 
and race (binary, nonwhite)
Table 3 — Odds ratio for upgrading from GS 6 tumor with PTEN protein loss
Discussion
 Biopsy GS underestimates the true GS in up to one third of cases, hindering the 
urologist’s ability to select optimal candidates for active surveillance. Here, we have 
shown that PTEN protein loss, assessed by a simple immunohistochemical (IHC) 
assay, is associated with tumor upgrading in GS6 biopsies. To our knowledge, this 
study is the first to support the utility of a single molecular marker in this setting. 
Compared to other types of biomarker assays, such as gene expression profiling 
arrays, one important advantage of PTEN IHC is that it is an inexpensive test that 
can easily be introduced into the workflow of any accredited pathology laboratory. 
Scored by a simple binary system, we have demonstrated low inter-observer vari-
ability for PTEN IHC by trained pathologist reviewers [16]. However, in cases with 
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indeterminate results, PTEN FISH will likely play a key role in resolving ambiguities, 
analogous to its use in the setting of Her2 assessment in breast cancer. Additionally, 
in our cohort of GS6 biopsies, PTEN gene deletions were frequently quite focal, 
thus PTEN IHC had the important advantage of focusing FISH scoring on the ap-
propriate area of the tumor, improving the speed and likely also the accuracy of 
FISH analysis.
The association of PTEN loss with tumor upgrading in GS6 needle biopsies sug-
gests that Gleason pattern 3 tumor associated with adjacent pattern 4 differs at 
the genomic level from pattern 3 derived from a purely GS6 tumor [24,27]. Indeed, 
using radical prostatectomy (RP) specimens, we have found that PTEN protein loss 
in pattern 3 carcinoma from a GS7 cancer is significantly more common than that 
of pattern 3 carcinoma from a purely GS6 tumor (AMD and Bruce Trock, in prepara-
tion). These studies suggest that an integrated approach exploiting genomic mark-
ers in limited tumor biopsy specimens will very likely improve on the prognostic 
accuracy of our current pathologic grading system. Such improvements are sorely 
needed to avoid overtreatment of indolent prostate cancers.
 In the current study, we report a very high correlation between PTEN IHC and 
FISH results. It is notable that such a large majority (87%) of cases with PTEN 
protein loss had underlying PTEN deletions in the current study. Given the general 
prevalence of hemizygous over homozygous deletions in previous PTEN FISH stud-
ies in localized prostate cancer [21,24], a surprising finding in the current study was 
that the majority of GS6 cases with PTEN protein loss showed homozygous PTEN 
gene deletion. This result may be attributable to the fact that we only performed 
PTEN FISH on cases showing PTEN protein loss by IHC. It is possible that the 
PTEN IHC assay may be relatively insensitive for detecting cases with hemizygous 
PTEN gene loss where protein levels may be somewhat lower compared to normal 
cases, but not markedly decreased due to the presence of one allele of the gene. 
It is also possible that focal/subclonal homozygous deletions in primary prostate 
cancer are more common than previously thought [28]. Future studies will examine 
whether hemizygous deletions may predict upgrading. If so, performance of IHC 
with FISH may represent the optimal strategy for risk assessment.
 Our study has a number of important strengths for routine clinical practice. Al-
though our patients were not enrolled in active surveillance protocols, 85% of them 
would have met the extended criteria for active surveillance recently evaluated 
at our institution [29], strongly suggesting that the results of the current study are 
relevant to this clinical setting. The vast majority of patients (>90%) in our study 
underwent an extended 12 core biopsy. Previous studies have demonstrated that 
biopsies consisting of fewer than 12 cores are associated with significantly higher 
upgrading rates than extended biopsies, which are currently the standard of care in 
the United States [12, 30]. Additionally, in our study, all RPs were entirely submitted 
for histologic examination, ensuring accurate Gleason score assignment. Finally, 
all biopsies and RPs were re-graded by urologic pathologists using the most up-
dated (2005) Gleason scoring system [26]. Our findings are further validated by the 
clinical-pathologic variables we found associated with upgrading, which are highly 
consistent with contemporary studies in much larger cohorts, including patient age, 
pre-operative PSA, clinical stage and extent of tumor involvement on biopsy [9–15]. 
As expected, upgraded patients in the current study also fared significantly worse 
after surgery, with substantially higher rates of extraprostatic extension, surgical 
margin positivity and biochemical recurrence compared to controls who were not 
upgraded at RP.
 There are a few potential weaknesses of the current study, perhaps the most 
important of which is the relatively small sample size. Because of this, it is essential 
that our results be validated in future studies with larger, prospective cohorts. Partly 
mitigating this weakness, our study did include patients from two clinical settings 
(tertiary vs. community care) yet each showed nearly identical rates of PTEN pro-
tein loss in upgraded cases and controls, suggesting that our findings will likely be 
reproducible in independent cohort analyses. An additional potential weakness is 
that we evaluated only one to two needle biopsy cores for most patients. Because 
we and others have showed that PTEN protein loss and underlying gene deletion 
is most commonly focal [24, 28], it is likely that we missed a number of cases with 
focal PTEN loss by evaluating PTEN status in only one core. Future studies and 
clinical implementation of our PTEN assay may require that all cancer-containing 
needle cores are evaluated for PTEN loss and this may substantially increase the 
sensitivity of our assay for predicting tumor upgrading in GS6 needle biopsies.
 In sum, with additional validation in larger cohorts, the PTEN IHC assay described 
herein may become an important part of the evaluation of prostate cancer patients 
being considered for active surveillance. It may be used alone on multiple involved 
needle cores from a single patient, or perhaps optimally in concert with FISH. In 
combination with MRI or other imaging tests to ensure the absence of unsampled 
anterior tumors, PTEN IHC is an inexpensive and simple test to assess for the pres-
ence of potentially unsampled higher grade disease in otherwise low risk patients.
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GENERAL DISCUSSION
 Prostate cancer is the most common visceral cancer diagnosed in men and, 
respectively, the second and third most frequently cause of cancer deaths in the 
United States and Europe (17, 18). Widespread PSA screening and aggressive 
treatment substantially reduced mortality rates of prostate cancer (19, 20). However,
the progresses in prostate cancer early detection lead to an overdiagnosis and 
overtreatment of indolent low grade cancers that would not be diagnosed clinically 
during life (20, 21). This fueled the debate about PSA screening because all treat-
ments for prostate cancer have potential long-term consequences for urinary and 
sexual function (22). Thus, it is mandatory to implement treatment strategies only 
in men who are likely to benefit from them and do not harm those patients with 
indolent tumors. A growing consensus in urological community supports an initial 
defer of treatment of indolent tumors using a strategy called active surveillance 
(23, 24). Men managed through active surveillance are monitored periodically to 
evaluate tumor progression so the patients can be treated within the window of op-
portunity to cure the cancer. In addition, the outcome of patients managed through 
active surveillance and subsequently required therapeutic intervention is identical 
with patients that initially received treatment (25, 26). Therefore, active surveillance 
is an important alternative to avoid or delay morbidity of prostate cancer treatment 
in a large subset of patients (27, 28).
 Prominent academic institutions established active surveillance programs, but the 
correct selection of candidates for these protocols and prediction of tumor progres-
sion are major challenges. A significant part of this quandary is due to the fact that 
prostate biopsies often fail to distinguish low-grade from high-grade tumors either due 
to sampling errors and imperfection of Gleason grading (29–31). Several studies esti-
mate that between 20% and 30% of tumors are incorrectly classified as low-grade and 
in reality contain high-grade features (28, 31, 32). In addition, Gleason score is still the 
strongest predictor of prognosis and there is a lack of precise molecular correlates of 
tumor progression. For this reason my work focused on three different stages of pros-
tate cancer evolution and cutoff of therapeutic intervention: cellular pathways involved 
in tumorigenesis and aggressiveness, Gleason score upgrading, and tumor-initiation 
capacity of cells that escape from the prostate to generate metastasis.
 Several new concepts emerged from this work describing the dynamics of Notch sig-
naling prostate cancer progression, the pivotal role of HES6 in tumor aggressiveness, 
the value of PTEN protein loss predicting Gleason score upgrade, and the isolation of 
viable CTCs to determine their biological activity. I will discuss in detail the most relevant 
results of the manuscripts presented in the previous chapters, because these findings 
may open new avenues for diagnostic and therapeutic targets in prostate cancer.
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Notch signaling in prostate: double-edge sword 
 Recent genome-wide expression profiles comparing low grade (Gleason ≤ 6) 
with high-grade (Gleason ≥ 8) tumors revealed enrichment for Notch pathway in 
aggressive cancers. In these studies, cancer cells with metastatic and lethal poten-
tial (Gleason ≥ 8) upregulated the Notch ligand JAGGED2, the NOTCH3 receptor, 
and a potential Notch target gene HES6. Although Notch signaling was recognized 
as an important pathway in several tumors (34), the contribution of these pathway 
members to prostate tumorigenesis was largely unkown. Moreover, in prostate can-
cer there were contradictory results about the oncogenic or tumor suppressive role 
of Nocth1 receptor in mouse and human models (35–37) contributing to a cloudy 
understanding of the role of Notch in prostate carcinogenesis. 
 In line with the gene expression studies performed in human tissue samples, 
our study confirmed that among all the members of Notch pathway the most highly 
express gene in cancer cell lines compared to benign was HES6. In these studies 
along with HES6, Notch3 was the other member of the pathway overexpressed 
in high grade cancer. However, in our global gene expression comparison be-
tween benign and cancer cell lines, we did not find a significant change for Notch3. 
After performing a subanalysis to find out the individual pattern of Notch pathway 
members expression in each cell line, we realized that one of the benign cell lines 
— RWPE1 — was the cell line with highest levels of Notch3, wiping out a higher 
expression in global analysis. When the subanalysis was performed without this cell 
line, HES6 and Notch3 were the most highly expressed genes in cancer cell lines. 
Another interesting finding was the fact that both Notch3 and HES6 were increased 
in two out of three androgen-responsive cancer cell lines (22Rv1 and LnCaP). So, 
we wondered if HES6 was a downstream target of Notch3 and they were regulated 
by androgens. Although HES6 is structurally homologous to known Notch3 targets, 
such as HES1 and HEY1, it was unknown whether Notch signaling regulates HES6. 
Our studies showed that HES6 acts independently of Notch3 and androgen stimula-
tion increases HES6 transcript levels. 
 Another important aspect is the dynamics of Notch signaling in prostate cells. 
Notch signaling largely emerged as having oncogenic effects in several tumor types 
and tumor suppressive functions were restricted to cutaneous squamous cell car-
cinomas (38). However, recent studies revealed tumor suppressive roles for Notch 
pathway in a wide variety of tumors (39–43). Yet none of these studies address 
potential tumor suppressive function in the prostate. We found that benign prostate 
cells expressed higher levels of Notch1 and Notch2 receptors and more Notch path-
way activation than cancer cells. Additional experiments demonstrated that prostate 
cancer cells do not respond to gamma secretase inhibition. 
 The last section of our Notch signaling studies focused on the independent roles 
of HES6 in tumor progression. By manipulating HES6 protein levels in benign and 
cancer cell lines, we discovered that HES6 controls the expression of genes in-
volved in cell invasion, apoptosis, chromatin remodeling, DNA repair, and modula-
tors of Hedgehog and Notch pathways. 
 Notch signaling dynamics and HES6 roles in prostate cancer bring up many inter-
esting questions for future research projects. Previous studies showed that although 
HES6 is structurally related with HES family members, it plays a feedback nega-
tive regulation of Notch signaling during neural stem cell differentiation by inhibiting 
Notch-responsive HES proteins (44, 45). So, besides HES6 independent functions 
controlling important pathways for tumor progression, future studies should explore 
potential inhibitory effects of HES and HEY targets levels in the context of cancer. 
 Another angle of this Notch story that is worth pursuing in the future relates with 
the ligands and receptors differentially expressed in benign compared to cancer 
cells. In line with previous studies (46, 47), we also found an upregulation of Notch3 
receptor in cancer cells. It was out of the scope of our study, but functional roles 
for Notch3 are being progressively implicated in the progression of different cancer 
types (48–53), including the prostate (54). For that reason, an interesting future 
line of research could be the comprehensive characterization of Notch3 functions’ 
in prostate tumors. Although, in our studies there was not a significant increase 
in Notch ligands expression, Gleason score 8 prostate cancers are enriched for 
Jagged2 (6). Because Jagged2 ligand and Notch3 receptor are overexpressed in 
high grade tumors, it is legitimate to speculate if there is an increased binding affinity 
between Jagged2 and Notch3 in cancer. Binding affinities of Notch receptors and 
ligands remain largely unknown, but there are descriptions for specific ligand-recep-
tor preferences. Delta4 and Notch1 actively interact to promote blood vessel forma-
tion (55–58) and recent work implicated Jagged2-Notch3 interaction in the context 
of T cell maturation (59). Because selective inhibitory antibodies against individual 
receptors are available (60), a better understanding of preferential ligand-receptor 
binding pairs is extremely relevant. By identifying which ligand-receptor interactions 
determine cancer phenotypes enable the specific Notch signaling blockade without 
the side effects of pan-notch inhibition (61). In conclusion, further studies character-
izing Notch pathway modulation are likely to translate into powerful diagnostic and 
therapeutic tools for prostate cancer.
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Loose PTEN to gain prognosis
 In addition to understanding the biology of prostate tumorigenesis, I was also 
interested in studying molecular biomarkers to improve patient selection for ac-
tive surveillance. As mentioned above, depending on the studies, 25% to 30% of 
supposedly indolent Gleason score 6 on needle biopsy are “upgraded” to Gleason 
score 7 or higher in the radical prostatectomy specimen. Several factors contrib-
ute to tumor upgrading, such as sampling error, tumor progression, and inter-
observer variability in Gleason grading. Unfortunately other clinical-pathological 
parameters such as PSA kinetics, prostate volume, more extensive disease on 
biopsy cores, or increasing number of sampled needle cores, are modest predic-
tors of Gleason grade upgrade. Thus, no molecular biomarkers were previously 
evaluated with the purpose of predicting tumor upgrading from needle biopsy to 
radical prostatectomy. 
 The loss of the tumor suppressor PTEN is one of the most common somatic aber-
rations in prostate cancer (62–69). Previous studies using applied IHC in high-risk 
cancers found that loss of PTEN protein staining is associated with poor clinical 
outcome (70, 71). Hence, we hypothesize whether PTEN IHC assay applied in a 
cohort of Gleason score 6 biopsies can predict Gleason upgrading in the radical 
prostatectomy specimen. 
 Our study showed a significant difference between PTEN protein loss in upgraded 
tumors compared to the controls (p=0.02). To confirm the IHC results, we performed 
FISH to determine PTEN gene deletions and found that 90% of the biopsies with 
decreased PTEN protein showed homozygous PTEN deletions. We then applied 
logistic regression models to determine the association of PTEN loss with tumor 
upgrade and found that, even adjusting for all predictors of upgrading described in 
multiple studies, tumors with PTEN loss were still significantly more likely upgraded 
at radical prostatectomy. 
 This is one of the first studies supporting the effectiveness of a single molecular 
marker in predicting Gleason score upgrading from needle biopsy to radical pros-
tatectomy. This finding opens several new lines of research and further validation 
of our results. Even though PTEN IHC is a quick and cheap assay, the logistic of 
collecting needle biopsies and radical prostatectomies takes a significant amount 
of time. Thus, to complete the study within the period of my Ph.D. research work, 
our cohort included patients whose biopsies and radical prostatectomies were 
performed at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Cen-
ter. This contributes for the relatively small retrospective cohort enriched for white 
ethnical background. In addition, although all our needle biopsies had Gleason 
score 6 tumors, our selection criteria did not meet the active surveillance used at 
Johns Hopkins Hospital (72). Therefore, our PTEN assay needs further validation 
in a larger prospective active surveillance cohort and include ethnical origins other 
than whites, such as african-american, which have adverse outcomes even with 
low-grade disease (73).
 In summary, PTEN IHC is a useful assay to predict Gleason score 6 upgrade, 
enabling better patient selection for active surveillance. 
Beyond detection of prostate circulating tumor cells 
 Finally, the last stage of prostate cancer progression that I addressed was the bio-
logical activity of prostate circulating tumor cells (CTCs). The majority of prostate-re-
lated deaths are consequence of hematogenously metastatic spread of tumor cells 
to the bone (74). In general, there is a temporal gap between the time cancer cells 
infiltrate distant organs and the development of metastatic lesions. Also, increas-
ing evidence supports the notion that tumor cells can disseminate from the earli-
est pre-neoplastic lesions, sometimes even before the formation of primary tumors 
(75–77). In prostate cancer, tumor recurrence is associated with pathological stage 
and Gleason score, but a provocative study demonstrated the presence of prostate 
cells in the bone marrow of 70% of patients with prostate cancer before radical 
prostatectomy (78). However, 15% of the patients with prostate cells in the bone 
marrow did not recur after 5 years of follow up. Several factors, such as short follow 
up time or tumor dormancy, can explain the absence of clinical recurrence, but it is 
reasonable to wonder if these cells cause or are simply a byproduct of metastasis.
 Less than 0.1% of the circulating cancer cells are estimated to survive the journey 
of infiltrating and colonizing distant organs (79, 80). So, a panoply of techniques and 
cell surface markers are currently used to isolate CTCs (81). Most of these meth-
ods rely on cell size or expression of the epithelial differentiation marker EpCAM 
that isolate only a fraction of CTCs. In addition, cells are unviable at the end of 
the protocols currently used to identify CTCs, precluding functional experiments. 
Although in patients with prostate cancer, high CTCs counts predict early death 
(82) and recurrence after radical prostatectomy (78), several lines of evidence 
showed that tumor cells downregulate EpCAM during epithelial-to-mesenchymal 
transition (EMT) to invade surrounding tissues (83) and metastasis-initiating cells 
need plasticity to switch between epithelial and mesenchymal states to entry in 
the bloodstream and for extravasate into distant organs. Therefore, I developed 
an unbiased method to isolate viable CTCs and generated mouse xenografts to 
determine their tumor-initiating capacity.
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 I used blood from men with castration-resistant prostate cancer and from TRAMP 
mice with metastatic disease. To preserve CTCs viability, I used gradient density 
centrifugation or red cell lysis followed by magnetic depletion of leucocytes with 
CD45 immunoaffinity beads. CTCs isolation from TRAMP mice and prostate cancer 
patients was confirmed by immunocytochemical staining, and inoculated into im-
munodeficient mice. Three months after injection, CTCs from TRAMP mice yielded 
invasive and highly aggressive tumors in 22% of recipients. Human CTCs did not 
successfully form tumors either when injected directly in the bloodstream or grafted 
under the kidney capsule to enhance grafting efficiency. Our results confirm that our 
CTCs isolation approach isolates viable CTCs with tumor-forming capacity without 
relying on cell surface markers. The success of TRAMP CTCs xenografts may have 
methodological and biological explanations: the amount of blood used in mouse 
experiments represented half of blood volume of each mouse whereas the human 
samples represented less than 0.5% of blood volume. It is also possible that the 
xenograft techniques developed so far for primary prostate tumors do not meet the 
growth requirements of CTCs or these cells need more than 8 months to establish 
a tumor. As mentioned above, prostate cancer cells have a latency period of in the 
bone longer than our follow up, which may have not allowed us to observe tumors. 
Most importantly, to our knowledge, this was the first study proposing an unbiased 
method to isolate viable CTCs and demonstrating in vivo their tumorigenic capacity.
 During the last decade, techniques to isolate circulating-free DNA present in the 
blood and identify genomic mutations present exclusively in tumors emerged as 
promising tools for cancer screening and monitoring therapeutic response (84). 
The sensitivity improvement of these assays and the rapid widespread of these 
technologies in several academic institutions will most likely relegate CTCs to a 
secondary plane as a diagnostic and therapy-response biomarkers, due to the lack 
of reliable cell surface markers and isolation techniques that identify the cells with 
true metastatic properties. Therefore, I believe that the study of CTCs should focus 
more on functional studies to identify lethal cell clones, their genetic and epigenetic 
alterations, rather than using several cell surface markers to enumerate different 
cell populations. Once the metastatic cell clones are identified, a plethora of assays 
to generate tumor-tissue in vitro, single-cell genomic analysis, and high-throughput 
drug screens can be performed to gain insights in individual tumors during disease 
progression and response to therapy.
 To conclude this general discussion, I would like to quote Susan Lindquist, a 
biologist whose pioneering works in yeast contributed for the understanding of 
protein folding in disease. Asked about her feelings about the current times in 
scientific research, Susan Lindquist answered: “This is the greatest intellectual 
revolution, and it is happening right now, and I’m lucky enough to be in the middle 
of it.” I feel the same! We have amazing tools to sequence whole-genomes in a few 
days or using overnight assays to determine the expression of thousands of genes. 
Throughout my PhD research work, I took advantage of these high-end techniques 
to indentify target genes and explore the biology of prostate cancer progression and, 
at the same, contribute to biomarker discovery for active surveillance.
CHAPTER 8 —
MAIN CONCLUSIONS
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MAIN CONCLUSIONS
1 Expression analysis of Notch pathway components in prostate cells revealed 
HES6 as the most differentially expressed gene between benign and cancer cells. 
HES6 transcritps are 4–fold higher in cancer.
2 Other targets of the Notch pathway such as HEY1, HEY2, and HES4 are 
also overexpressed in cancer cells. In contrast, many central Notch signaling 
components, as DLL1, JAG1, NOTCH1, NOTCH2, and NOTCH4 receptors, are 
downregulated in cancer. 
3 Most of prostate androgen-responsive cell lines have a high expression of both 
NOTCH3 and HES6. However, NOTCH3 and HES6 act independently in prostate 
cancer progression. 
4 Benign prostate cells have significantly higher expression of Notch1 and 
Notch2 receptors and preserved canonical Notch signaling. Consequently, Notch 
receptors are cleaved by g-secretase and strongly activate RBPJ. On the contrary, 
the majority of prostate cancer cells have lower expression of Notch1 and Notch2 
receptors, which are not cleaved by g-secretase. For this reason, pharmacological 
inhibition of the Notch pathway does not affect prostate cancer cells viability 
and growth. Therefore, targeting Notch is unlikely to be a successful strategy for 
treating prostate cancer.
5 Androgens affect the expression of Notch receptors and targets in opposite 
directions. Androgen stimulation decreases NOTCH1, NOTCH2, and NOTCH3 
expression over time whereas HES1, HES6, and HEY1 increase. Thus, androgens 
may induce HES/HEY family members in a Notch receptor-independent manner. 
6 HES6 is a key player of Notch prostate cancer progression and metastatic 
potential. HES8 significantly affected the clonogenic potential and invasion 
capacity of cancer cells.
7 HES6 controls members of several pathways, such as kinases, apoptosis, 
hedgehog, and integrins, that are implicated in the invasion and clonogenic 
advantage observed in cancer cells.
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8 PTEN IHC is an useful assay to predict upgrading of Gleason score 6 cancers 
from biopsies to radical prostatectomy.
9 PTEN protein loss in both nuclear and cytoplasmic compartments is present in 
18.3% of upgraded cases comparing to only 6.8% of not upgraded tumors (p=0.02)
10 FISH confirmed that 90% of the biopsies with decreased PTEN protein 
expression have homozygous deletion of PTEN gene.
11 Logistic regression determined PTEN loss as an independent predictor 
of tumor upgrading. Even after adjusting for age, preoperative PSA, clinical 
stage and race, Gleason score 6 tumors with PTEN protein loss on biopsy are 
significantly more likely to be upgraded at radical prostatectomy [OR=3.04 (1.08–
8.55; p=0.035)].
12 A novel unbiased approach can isolate viable CTCs present in the 
bloodstream of TRAMP mice and prostate cancer patients with castration-resistant 
disease.
13 CTCs isolated using gradient density centrifugation or red cell lysis followed 
by magnetic separation of CD45 cells express cytokeratin 8 and EpCAM.
14 CTCs from TRAMP mice isolated using our method, are able to form new 
tumors in immunodeficient hosts.
15 None of human CTCs formed tumors, suggesting a relatively low tumor-
forming potential.
16 Rather than quantifying heterogeneous cell populations present in the blood, 
future studies should identify and target the highly tumorigenic fraction of CTCs.
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Abstract
 This thesis covers molecular mechanisms involved in major steps of prostate 
cancer progression such as the roles of Notch pathway and HES6 in tumor aggres-
siveness, identification of PTEN loss as a predictor of Gleason score upgrading, and 
the isolation of cells with tumor-initiation capacity that escape from the prostate to 
generate metastasis.
 PSA screening contributes to the early detection of prostate cancer. However, 
the results of randomized PSA screening studies raised issues of overdiagnosis 
and overtretament of indolent prostate cancers. One way to decrease prostate can-
cer overtreatment is through “Active surveillance”. Some of the most widely and 
accepted criteria to enroll patients in active surveillance protocols are early stage 
tumors with low grade Gleason score. Although the Gleason grading system is the 
strongest prognostic predictor after radical prostatectomy, due to sampling errors 
it is less powerful when analyzed in biopsies. So, one of the major questions that 
remain to be addressed is how to find biomarkers or pathways that can distinguish 
indolent from lethal tumors. 
 Recent work supports the notion that expression levels of Notch pathway mem-
bers can serve this purpose. Gene expression profiling analysis on cancer cells from 
localized prostate cancers that were purely high-grade (Gleason 4+4=8) or purely 
low grade (Gleason 3+3=6) revealed that Notch signaling was the theme most as-
sociated with genes that distinguish between indolent and aggressive cancer cells. 
Our studies showed significantly higher expression of NOTCH3 and HES6 transcripts 
in cancer cells compared with benign cells. The expression of these Notch pathway 
receptor and target was particularly high in androgen-responsive lines 22Rv1 and 
LnCaP. Prostate cancer cells responded to Notch stimulation by induction of Notch 
canonical targets, HES1 and HEY1, but not HES6. We found that androgen stimula-
tion also induced HES1 and HEY1, while downregulating Notch receptors, suggesting 
that androgens can activate Notch target genes in a receptor-independent manner. 
To study the dynamics of Notch signaling in prostate cells, we used a Notch-sensitive 
RBPJ reporter assay and realized that prostate cancer cells downregulated Notch 
signaling. Consequently Notch pathway blockade with γ-secretase inhibitor was un-
able to restrain cancer cell growth or viability. In contrast, HES6 expression was 
independent of Notch signaling, but as mentioned above, relied on androgen levels 
in culture. We confirmed androgen-dependent HES6 expression in human prostate 
cancer tissues from patients treated with androgen deprivation. We complemented 
HES6 expression studies with functional assays using shRNA downregulation of 
HES6 in cancer cells. We revealed functions for this gene product in prostate cancer 
cells to form colonies from single cells and cell invasion. By molecular profiling of 
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pathways controlled by HES6 we identified potential roles for this transcription fac-
tor in regulating hedgehog signaling, apoptosis, and cell migration. Thus, our work 
contraindicate an oncogenic role for Notch signaling in the prostate, but implicates 
HES6 as a protagonist in prostate cancer progression.
 Having mind the clinical challenge that tumor progression represents for men 
with low grade cancer on active surveillance programs, we took advantage of PTEN 
loss, a characteristic genomic alteration of high Gleason score and metastatic tu-
mors, and explore its potential to identify high risk cancers. We design a retrospec-
tive case-control study with 71 patients with GS 6 tumors on needle biopsy that 
were upgraded to GS 7 or higher cancer at RP (cases) and compared them to 103 
patients whose GS 6 tumors on needle biopsy were not upgraded at RP (controls). 
Then, we performed IHC and scored for PTEN protein loss on prostate needle core 
biopsies with Gleason score 6. Biopsies with PTEN protein loss by IHC were fur-
ther analysed using FISH to detect PTEN gene deletion. Our IHC results showed 
PTEN protein loss in 18.3% (13/71) of upgraded cases compared to 6.8% (7/103) 
of controls (p=0.02). In the cases where IHC did not detect PTEN expression, FISH 
confirmed homozygous PTEN deletion in 90% (9/10) of upgraded tumors compared 
to 67% (4/6) of interpretable controls who were not upgraded. Multivariate analyses 
adjusted for age, preoperative PSA, clinical stage and race, established that Glea-
son score 6 tumors with PTEN protein loss on biopsy were significantly more likely 
to be upgraded at radical prostatectomy [odds ratio = 3.04 (1.08–8.55; p=0.035)] 
compared to those without PTEN loss. Overall, PTEN IHC is a simple and cheap 
assay that effectively distinguishes men candidates for active surveillance with low 
risk cancers from men with intermediate or higher risk cancers.
 Finally, cancer cells from high Gleason grade (Gleason score ≥ 7) tumors have 
the potential to escape from the prostate and generate metastasis in distant organs. 
The promise that detection of CTCs might change cancer prognosis and thera-
peutic response monitoring, lead to the development of several detection methods. 
However, most of these methods are biased towards isolation of subpopulations of 
CTCs that might not represent cells with true metastatic-initiation capacity. Thus, we 
developed an unbiased approach to isolate viable CTCs from a transgenic mouse 
model of prostate cancer (TRAMP) and men with castration-resistant disease. After 
identifying the presence of CTCs, we inoculated into immunodeficient mice to de-
termine the tumorigenic potential of these cells. Three months after injecting CTCs 
from TRAMP into immunodeficient hosts, these developed metastasis with highly 
aggressive features, similar to the primary tumors. Although CTCs from prostate 
cancer patients did not formed tumors, our isolation method showed to be effective 
in isolating viable CTCs without relying on cell surface markers or size fractionation. 
Future studies should focus on identifying and target the highly tumorigenic cells to 
have significant impact in prostate cancer prognosis.
Resumo
 Esta tese abrange os mecanismos moleculares envolvidos em algumas das prin-
cipais etapas de progressão do cancro da próstata como o papel da via do Notch e 
do HES6 na agressividade tumoral, a identificação da perda de PTEN como preditor 
do aumento do score de Gleason e o isolamento de células neoplásicas prostáticas 
na circulação sanguínea e com capacidade de gerar metástases.
 O rastreio baseado no PSA contribui para a detecção precoce do cancro da 
próstata. Contudo, resultados recentes de ensaios clínicos randomizados indicam 
que o screening com PSA leva a um sobrediagnóstico e sobretratamento de can-
cros da próstata indolentes. Uma forma de diminuir este sobretratamento consiste 
na “vigilância ativa”. A maioria dos doentes que integram programas de vigilância 
ativa têm tumores em estadio inicial e de baixo score de Gleason. No entanto, ape-
sar do sistema de classificação de Gleason ser o principal preditor de prognóstico 
após prostatectomia radical, os erros de amostragem na biopsia fazem com que 
este parâmetro seja muito menos poderoso quando avaliado em biópsias. Por esse 
motivo, torna-se fundamental encontrar biomarcadores ou vias moleculares que 
distingam tumores indolentes dos letais. 
 Trabalhos recentes mostraram que os níveis de expressão de membros da via de 
sinalização Notch podem responder a esta problemática. A analise da expressão 
génica de células cancerígenas presentes em tumores localizados que eram pura-
mente de alto grau (Gleason 4+4=8) ou puramente baixo grau (Gleason 3+3=6) 
revelou que o Notch era a via mais associada a genes que distinguem entre tumores 
indolentes e agressivos. Os nossos estudos mostraram um aumento significativo 
do nível de transcritos NOTCH3 e HES6 nas células cancerígenas comparando 
com células benignas. A expressão deste receptor e alvo da via foi particularmente 
elevada nas linhas celulares que respondem a androgénios, 22Rv1 e LnCaP. De 
forma a verficar se HES6 seria controlado pela sinalização Notch, estimulamos 
linhas celulares de cancro da próstata que responderam, com a indução de alvos 
canónicos, como HES1 e HEY1, mas não HES6. Adicionalmente, a estimulação 
das células com androgénios induziu a expressão dos alvos HES1 e HEY1, mas 
diminuiu a expressão dos receptores respectivos. Estes resultados sugerem que 
os androgénios activam alvos da via Notch de uma forma independente dos re-
ceptores. Para estudar a dinâmica desta via de sinalização em células prostáticas, 
usamos um vector com o gene RBPJ associado a um sinalizador de luciferase. Os 
resultados deste ensaio mostraram que as células de cancro da próstata diminuem 
a intensidade da sinalização Notch. Em consequência, o bloqueio farmacológico 
da via com um inibidor da γ-secretase foi incapaz de suprimir a multiplicação das 
células tumorais. Por outro lado, a expressão de HES6 mostrou-se independente 
da via de sinalização de Notch, mas como atrás mencionado, dependerá dos níveis 
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de androgénios no meio de cultura. Confirmamos a dependência da expressão de 
HES6 dos androgénios através da análise imunohistoquímica de tumores do can-
cro da próstata provenientes de doentes submetidos a terapêutica hormonal. Estes 
estudos da expressão de HES6 foram complementados com estudos funcionais 
utilizando o silenciamento deste gene nas células cancerígenas por RNA de inter-
ferência. Os nossos estudos mostraram que este gene está envolvido na formação 
de colónias de células malignas e na invasão da membrana basal. Depois de re-
alizar o perfil molecular das vias controladas por HES6, identificamos potencias 
funções deste gene na regulação da via do hedgehog, apoptose e migração celular. 
Assim, o nosso trabalho sugere que a via de sinalização de Notch possivelmente 
não tem um papel oncogénico no cancro da próstata, mas implicam HES6 como um 
protagonista na progressão desta neoplasia. 
 Tendo em conta o desafio que representa para o urologista saber se os tumores 
dos doentes em vigilância ativa vão progredir para estádios mais avançados, de-
cidimos explorar o potencial do gene PTEN como biomarcador. Estudos prévios 
mostraram que a perda do gene PTEN é frequente em tumores de elevado grau 
de Gleason e em metástases. Por isso a nossa hipótese consistiu em verificar se 
a perda da expressão da proteína PTEN em biópsias de tumores Gleason 6 pred-
izia o aumento do score de Gleason na prostatectomia radical. Realizamos, então, 
um estudo retrospectivo caso-controlo, com 71 doentes portadores de carcinomas 
Gleason 6 na biopsia, mas cuja peça operatória de prostatectomia radical mostrou 
tumores com score de Gleason mais elevados (Casos); os quais foram comparados 
com 103 doentes cujo score de Gleason na biopsia e na peca operatória se man-
teve como 6 (Controlos). Avaliamos por imunohistoquímica a perda de expressão 
da proteína PTEN em todas as biópsias Gleason 6. As biópsias que apresentavam 
perda de proteína por imunohisotquimica foram analisadas com FISH para detectar 
deleções do gene PTEN. Os resultados de imunohistoquímica mostraram perda de 
expressão de PTEN em 18,3% (13/71) dos casos comparando com 6,8% (7/103) 
dos controlos (p=0,02). Em casos onde não se detectou expressão de PTEN, a 
técnica de FISH confirmou deleção homozigotica de PTEN em 90% (9/10) compa-
rando com 67% (4/6) dos controlos. A analise multivariada ajustada para a idade, 
PSA pré-operatório, estadio clínico e raça, estabeleceu que nos tumores com um 
score de Gleason 6 com perda de expressão proteica de PTEN na biopsia existia 
uma probabilidade significativamente maior de ser atribuído um score de Gleason 
mais elevado na prostatectomia radical [odds ratio = 3.04 (1.08–8.55; p=0.035)]. 
Concluímos que a imunohistoquímica para PTEN, um teste simples e barato, dis-
tingue de forma eficaz pacientes com tumores de baixo grau candidatos a vigilância 
ativa dos portadores de tumores de risco intermédio ou alto. 
 Finalmente, tumores com elevado score de Gleason (superior ou igual a 7) têm 
o potencial para invadir e gerar metástases em órgãos distantes. A expectativa 
de que a detecção de células tumorais circulantes (CTCs) poderá melhorar o prog-
nóstico ou a monitorização da resposta terapêutica, levou ao desenvolvimento de 
vários métodos para detectar estas células. Contudo, a maioria dos métodos de de-
tecção de CTCs têm o viés de isolarem subpopulações de células que podem não 
representar aquelas com verdadeira capacidade de iniciar metástases. Por isso, 
desenvolvemos uma abordagem independente de isolamento de CTCs viáveis, 
utilizando um modelo de ratinho trangénico de cancro da próstata (TRAMP) e o 
sangue de pacientes com tumores hormono-resistentes. Depois de identificarmos a 
presença de CTCs isoladas por este método, inoculamos essas células em ratinhos 
imunodeficientes para determinar o potencial tumorigenico das CTCs. Três meses 
após inocularmos CTCs provenientes dos ratinhos TRAMP nos hospedeiros imu-
nodeficientes, estes desenvolveram metástases com características muito agres-
sivas, semelhantes aos dos tumores primários. Apesar das CTCs provenientes 
de doentes com cancro da próstata não terem formado tumores, o nosso método 
provou isolar eficazmente e de forma independente CTCs viáveis. Para que ocorra 
um impacto significativo destes achados no prognóstico dos pacientes com cancro 
da próstata, estudos futuros devem centrar-se na identificação das CTCs altamente 
tumorigénicas, as quais poderão constituir um alvo terapêutico preferencial. 
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